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Abstract 
Hepatic regeneration is essential for the success of living donor liver transplantation 
(LDLT) in which the residual liver in donor and the segment that is transplanted into the 
recipient will grow in size to accommodate the requirements of the donor and recipient. 
We hypothesized that the clearance of drugs will be drastically reduced during the 
immediate post operative period in donor and recipient due to reduced liver mass and the 
decreased activity of the drug metabolizing enzymes in the liver. The objectives of this 
dissertation are to evaluate 1) the mRNA expression and in vitro and in vivo activity 
(pharmacokinetics of tacrolimus) of CYP3A; 2) the effect of hepatotropic drugs such as 
cyclosporine and tacrolimus on the activity of CYP3A; 3) the expression, and in vitro and 
in vivo activity (pharmacokinetics of mycophenolic acid) of various uridine diphosphate 
glucuronosyltransferases; and 4) the in vivo metabolism of acetaminophen in rats, during 
hepatic regeneration after partial hepatectomy. 
 
Our results indicate that 1) the activity of most of the drug metabolizing enzymes was 
decreased but recovered completely at different rates; 2) the mRNA expression mirrored 
the changes in in vitro activity of these enzymes; 3) the clearance of tacrolimus and 
 iii
mycophenolic acid was decreased but recovered completely at different rates; 4) the 
magnitude of reduction in in vivo clearance of tacrolimus and mycophenolic acid was 
much less than what was predicted from the loss of liver mass and reduction in enzyme 
activity; 5) cyclosporine and tacrolimus did not have any significant effect on the 
recovery of activity of CYP3A, and 6) there was increased production of toxic 
metabolites of acetaminophen during regeneration. 
 
The clinical implications of our study are as follows: 1) Drug dosing in LDLT patients 
should be carefully monitored. A less than proportionate decrease in dose relative to 
reduction in liver mass may be necessary for different drugs. 2) The drug elimination 
capacity of the liver recovers completely with time and normal hepatic function will be 
restored in subjects undergoing hepatic resection. 3) Recovery of hepatic function will 
proceed normally in presence of hepatotropic substrates such as cyclosporine A and 
tacrolimus. 
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Chapter 1 Introduction 
 
Background: 
Liver Transplantation  
Liver transplantation is the treatment of choice for patients with end-stage liver disease or 
certain metabolic liver disorders where no other alternative therapies are available. 
Successful liver transplantation has led to a one year patient and graft survival rate 
exceeding 90%. Currently, the cadaveric livers are the primary source of organ for liver 
transplantation. However, the numbers of available cadaveric organs are not sufficient for 
the numbers of patients on the waiting list for liver transplantation. The increased number 
of patients requiring transplantation and the stagnant number of cadaveric organs 
available for transplantation has increased the waiting time and has led to a high mortality 
for patients on the waiting list (Shiffman et al, 2002).  
 
A number of techniques have been developed to deal with the shortage of cadaveric 
organs (Wiesner et al., 2003): 1) Use of livers from marginal donors who are older than 
55 years of age; who have fatty infiltration of the liver; who have diabetes mellitus; and 
who are hepatitis c virus (HCV) or hepatitis B virus (HBV) positive; 2) performing split 
liver transplantation in which a cadaveric liver is split into 2 pieces, with one piece being 
used for an adult recipient and the other being used for a pediatric recipient (Rogiers et al., 
1996; Busuttil and Gross, 1999; Rela et al. 1998); 3) performing domino transplantation 
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in which the first patient receives a liver from a donor and donates her/his liver to another 
patient (Stangou et al., 1998); 4) performing living donor liver transplantation (LDLT) in 
which the right liver lobe (account for the removal of up to 60% to 65% of the liver), is 
removed from the donor and transplanted into the recipient (Seaman, 2001). 
 
Living Donor Liver Transplantation 
Adult living donor liver transplantation is based on the ability of the adult liver to 
regenerate to accommodate the requirements in both the donors and the recipients. Living 
donor liver transplantation has emerged as an effective therapy for some patients with 
end-stage liver diseases and is also a partial solution for the current shortage of cardaveric 
organs. The living donor liver transplantation was initiated originally with the concept of 
grafting a segment of a liver from a living donor into a child who needed liver 
transplantation. The success of living donor liver transplantation in the pediatric patients 
led to the application of this surgery to adult-to-adult living donor liver transplantation. 
Interestingly, the recipients in the LDLT program had higher survival rates than those 
receiving cadaveric grafts (Rosendale et al., 1997; Sindhi et al., 1999; Jurim et al., 1995) 
due to less cold ischemia, better quality of the graft because of the healthy status of the 
donor, appropriate size of the vessels, and stable status of the recipient in this relatively 
elective procedure (Seaman, 2001). 
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In the United States, the first series of adult living donor liver transplantation was 
conducted in 1998 (Wachs et al., 1998). Since then, there has been great interest in adult 
living donor liver transplantation not only within the transplant medical community, but 
also among patients and their families who desire to become liver donors (Shiffman et al., 
2002).  
 
Hepatic Regeneration 
Hepatic regeneration is very critical for the success of the adult living donor liver 
transplantation. The unique ability of the liver to regenerate was first recognized in the 
Greek mythology of Prometheus. The regenerative responses are proportional to the 
amount of liver removed in animals and humans and even small resections (< 10%) can 
trigger a response that restores the liver to full size (Michalopoulos and DeFrances, 1997). 
The liver regeneration process involves proliferation of all the existing mature cellular 
populations within the liver, including hepatocytes, biliary epithelial cells, fenestrated 
endothelial cells, kupffer cells, and cells of Ito (Michalopoulos and DeFrances, 1997). 
After partial hepatectomy, hepatocyte proliferation first begins in the periportal region, 
which is the first to receive the portal blood flow.  
 
The exact signals that trigger the onset of hepatic regeneration are still not well defined. 
However, it is believed that hepatocyte growth factor (HGF) and its receptor, c-Met are 
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key components for the hepatic regeneration since a dramatic increase in plasma 
concentration of HGF has been observed after hepatic resection both in humans and rats 
(Schmidt et al., 1995; Tomiya et al., 1992). The rapid rise of HGF in the plasma is 
believed to be the mitogenic stimulus leading hepatocytes into DNA synthesis 
(Michalopoulos and DeFrances, 1997). However, the causes for the increase in plasma 
HGF are not entirely clear. Several cytokines are also involved in hepatic regeneration. 
Tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) are necessary for the remnant 
liver to regenerate after two thirds hepatectomy. A significantly increased IL-6 plasma 
concentration has been observed after partial hepatectomy in humans and rats 
(Matsunami et al., 1992; Fulop et al., 2001). IL-6 has been reported to be mitogenic and 
lack of IL-6 can suppress hepatocyte DNA synthesis (Kordula et al., 1990; Cressman et 
al., 1996). A lack of TNF-α (either due to treatment with antibodies or in TNF-α 
knock-out mice) also resulted in decreased DNA synthesis or inhibition of hepatic 
regeneration after partial hepatectomy (Diehl et al., 1994; Akerman et al., 1992; Yamada 
et al., 1997). In addition, epidermal growth factor, transforming growth factor, 
norepinephrine and insulin are also involved in triggering hepatic regeneration 
(Michalopoulos and DeFrances, 1997). 
 
A large number of genes are either newly expressed or increased in their expression after 
partial hepatectomy. The first phase of gene expression after partial hepatectomy, namely 
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the immediate early phase, occurs very rapidly after PHx and lasts for approximately 4 
hours (Fausto, 2000). As many as 70 genes participate in the immediate early response to 
partial hepatectomy (Haber et al., 1993). An important advance in understanding liver 
regeneration is the observation that transcription factors such as NF-κB, AP-1, C/EBP-β 
and STAT-3 are activated after partial hepatectomy (Fauto, 2000). 
 
Our current understanding of liver regeneration forms the basis for the treatment of many 
liver diseases, living donor liver transplantation and the application of hepatic tissue 
engineering (Palmes and Spiegel, 2004). These advances have been achieved primarily 
by studies of liver regeneration in animals (Palmes and Spiegel, 2004). 
 
Models for Studying Hepatic Regeneration 
In general, two strategies have been adopted for the experimental initiation of liver 
regeneration in animals: surgical resection or injury by toxins (Palmes and Spiegel, 2004). 
Partial hepatectomy, portal branch ligation, portosystemic shunting and direct 
compensatory hyperplasia are surgical techniques that are used to initiate liver 
regeneration, while carbon tetrahydrochloride, D-galactosamin, thioacetamide, 
acetaminophen and ethanol are toxins that are used to initiate liver regeneration (Palmes 
and Spiegel, 2004). The 2/3 hepatectomy procedure (Figure 1) in the rat devised many 
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years ago by Higgins and Anderson (1931) has found broad acceptance (Palmes and 
Spiegel, 2004). The advantages of using a rat to study liver regeneration after 2/3 
hepatectomy are: 1) a high level of accuracy (e.g., the liver deficit after 2/3 resection is 
nearly always 68%), and reproducibility due to the uniform and consistent anatomy of the 
rat; 2) a simple operation requring no more than basic surgical skills; 3) good tolerance 
by the rats without perioperative mortality (Palmes and Spiegel, 2004). This experimental 
approach was chosen for the current project. 
               
Figure 1. Surgical model of 2/3 partial hepatectomy. Medial and left lobes are 
surgically removed during PHx. 
 
Drug Metabolism (aspects related to hepatic regeneration and living donor liver 
transplantation) 
1. Drug metabolizing enzymes and transporters 
Cytochrome P450 (CYP) is the most important phase I enzyme and refers to a 
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superfamily of heme-containing enzymes located in the membrane of the endoplasmic 
reticulum of the cell. CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A 
enzymes are responsible for the majority of phase I metabolism (Bertz and Granneman, 
1997). Among these enzymes, CYP3A is the most abundant isoform in human livers. It 
constitutes about 30% of the CYPs in human liver followed by CYP2C, CYP1A2, 
CYP2E1 and CYP2D6, which represent 20%, 13%, 7% and 2%, respectively (Shimada et 
al., 1994; Eagling et al., 1998; Glue and Clement, 1999). Functionally, CYP3A4 
metabolizes about 53% of the commonly prescribed drugs, followed by CYP2D6, 
CYP2C, CYP1A2 and CYP2E1 accounting for 25%, 18%, 3% and 1%, respectively 
(Bertz and Granneman, 1997).  
 
The subfamily of CYP3A includes CYP3A4, CYP3A5, and CYP3A7. CYP3A4 is the 
major isoform in the liver as well as the small intestine of adult human. CYP3A5 is 
expressed in 20% of the population, while CYP3A7 is only expressed in the fetal liver 
(Venkatakrishnan et al., 2001). CYP3A is involved in the metabolism of tacrolimus, 
cyclosporine A, sirolimus and testosterone. In rats, CYP3A constitutes 17% of the total 
CYPs and includes CYP3A1, CYP3A2 and CYP3A23 (Waxman, 1999). 
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Uridine Diphosphate Glucuronosyltransfereases (UGTs) are an important superfamily of 
phase II membrane bound enzymes located in the endoplasmic reticulum. These enzymes 
catalyze glucuronidation of endogenous and exogenous compounds such as estradiol, 
acetaminophen, morphine, androsterone, testosterone and mycophenolic acid. UGTs exist 
in two subfamilies designated as UGT1A and UGT2B (Mackenzie et al., 1997). There are 
a total of 9 isoforms of UGT1 (UGT1A1, UGT1A2, UGT1A3, UGT1A4, UGT1A5, 
UGT1A6, UGT1A7, UGT1A8 and UGT1A9) in rats. However, UGT1A4 and UGT1A9 
are pseudogenes in rats. Even though there are some differences in UGT1A isoforms 
between humans and rats, most of UGT1A isoforms (UGT1A1, UGT1A3, UGT1A5, 
UGT1A6, UGT1A7 and UGT1A8) are common functional isoforms of UGT1A family in 
human and rats (Mackenzie et al., 1997). Rats have six isoforms of the UGT2B family 
(UGT2B1, UGT2B2, UGT2B3, UGT2B6, UGT2B8 and UGT2B12) (Mackenzie et al., 
1997). Since isoforms of the UGT2B subfamily were named in the order that they were 
cloned, there is no information available on the corresponding isoforms of UGT2B in 
humans.  
 
In addition to drug metabolizing enzymes, drug transporters also influence the 
pharmacokinetics of several drugs. Efflux of drugs from cells is mediated by several 
members of ATP-binding cassette (ABC) superfamily such as P-glycoprotein, multidrug 
resistance protein (Mrp) 1, Mrp2, Mrp3, Mrp4, Mrp5 and Mrp6. Among these tranporters, 
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P-glycoprotein, Mrp1, Mrp2 and Mrp3 contribute to a significant degree to the overall 
elimination of drugs. P-glycoprotein plays an important role in limiting the bioavailability 
of drugs from the gut, excretion of drugs into bile and protection of the brain by 
functioning as a blood-brain barrier (Kimura et al., 2004). Multidrug resistance protein 1 
and Mrp3 are found in basolateral membranes and play a role in uptake of drugs in most 
tissues of human body. Multidrug resistance protein 2 is different from Mrp1 and Mrp3 in 
that it is located on the apical plasma membranes of polarized cells in liver, small 
intestine and brain (Haimeur et al., 2004). 
 
2. Regulation of Drug Metabolism (cytokines released during hepatic regeneration may 
alter the activity of drug metabolizing enzyme) 
Different types of tissue damage (injury or infection) leads to induction of a series of 
secretory proteins, the acute-phase proteins (APP) (Morgan, 1997). The APP response to 
inflammation is mediated by cytokines such as IL-6, IL-1, and TNF α (Baumann and 
Gauldie, 1994; Koj, 1996; Moshage et al., 1990). An inflammatory response is initiated 
by the release of TNF α and IL-1 which will stimulate the further release of IL-1 and IL-6 
(Baumann and Gauldie, 1994; Watkins et al., 1995). Even though IL-1 and TNF α are 
detectable in plasma, IL-6 levels are generally much higher (Lowry, 1993).  
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2.1 Cytochrome P450 
Various reports have shown that IL-6, IL-1 and TNF α have selective suppressive effect 
on the expression and activity of different CYPs in in vivo and in vitro systems such as 
primary hepatocytes and microsomes (Morgan, 2001). The possible role of TNF-α in the 
down-regulation of CYP was studied using TNF-α receptor deficient mice. The results 
showed that TNF-α does not play a significant role in the down-regulation of CYP after 
administration of lipopolysaccharide (Warren et al., 1999). However, strong evidence 
indicated IL-6, the most important cytokine modulating acute-phase protein genes, to be a 
key player in the down-regulation of hepatic CYPs (Siewer et al., 2000). 
 
In addition, nitric oxide generated from hepatocytes and kupffer cell in response to 
cytokines and inflammation is able to react with heme-containing proteins such as CYP 
enzymes and can decrease CYP-mediated activities (Khatsenko et al., 1993; Hakkola et 
al., 2003). Furthermore, nitric oxide can also inhibit the expression of some P450s 
(Khatsenko and Kikkawa, 1997; Hara and Adachi, 2002). Therefore, inflammatory 
cytokines and nitric oxide may contribute to the down-regulation of P450s during 
inflammation (Hakkola et al., 2003). 
 
Since most of the suppressive effects of cytokines on CYPs take place at the transcription 
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level, there must be some regulatory factors involved in this process. Among many 
characterized transcription factors, liver-enriched transcription factors such as hepatocyte 
nuclear factor (HNF)-1α, HNF-4α and CCAAT/enhancer-binding proteins (C/EBP ) 
appear to be involved in the liver-specific expression of CYP genes (HNF-1α: CYP2E1, 
CYP7A1 and CYP1A2; HNF-4α: CYP2C9 and CYP2D6; C/EBP : CYP2B) (Akiyama 
and Gonzalez, 2003). The nuclear receptors such as pregnane X receptor (PXR), 
constitutive androstane receptor (CAR), farnesol X receptor (FXR) are also involved in 
control of CYP genes (PXR: CYP3A4 and CYP2B6; CAR: CYP3A and CYP2B; FXR: 
CYP7A1) (Akiyama and Gonzalez, 2003).  
 
Nuclear receptors such as CAR and PXR are responsible for the induction of some CYPs 
such as CYP2B and CYP3A at the transcriptional level. Phenobarbital and rifampicin are 
representative ligands for the activation of CAR and PXR. The functional feature of CAR 
and PXR is overlapped in the genes regulated by these receptors and the ligands to 
activate these receptors. However, recent findings pointed that the expression of CAR and 
PXR is down-regulated and these receptors are also responsible for the basal level of the 
expression of CYPs during acute phase response in vitro and in vivo (Pascussi et al., 2000; 
Beigneux et al., 2002).  
 
2.2 Uridine Diphosphate Glucuronosyltransferases (UGTs) 
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Compared to the effects of cytokines and inflammation on the expression or activity of 
CYPs, there are limited reports of their effects on the expression or activity of UGTs. 
Levesque et al. (1998) reported that IL-1α inhibited the formation of dihydrotestosterone 
glucuronide in LNCaP cells. After turpentine injection in rats, the rate of p-nitrophenol 
glucuronidation (UGT1A6 in rats) by hepatic microsomes was not changed, while the 
formation of testosterone glucuronide (UGT2B1/3/6) was reduced to 65% of the control 
level (Strasser et al., 1998). The mRNA expression of both UGT1A1 and UGT2B3 was 
also decreased after injection of turpentine (Strasser et al., 1998). IL-6 suppressed the 
mRNA expression of UGT1A1 and UGT2B3 in primary rat hepatocytes at 50 u/ml 
(Strasser et al., 1998).  
 
Studies on UGT gene expression and regulation have also been carried out in rodents. 
The promoter region of UGT2B1 contained HNF1 and CCAAT-Enhancer Binding 
Protein (C/EBP) binding sites (Mackenzie et al., 2003). Subsequent studies have shown 
that nuclear protein complexes containing HNF-1α or C/EBP α respectively bind to these 
sites and enhanced the transcriptional activity of the UGT2B1 promoter (Hansen et al., 
1997; Hansen et al., 1998). Disruption of the C/EBP α gene results in complete loss of 
expression of UGT1A1 in mice (Lee et al., 1997). In addition to HNF-1α and C/EBP α, 
other transcription factors such as Octamer Transcription Factor 1 (Oct-1) and Pre B cell 
homeobox-2 (Pbx 2) regulate the expression of UGTs by interacting or interfering with 
HNF1 (Mackenzie et al., 2003). The expression of UGTs can also be induced through 
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activiation of nuclear receptors such as CAR and PXR by various inducers (ligands) 
(Mackenzie et al., 2003). 
 
3. Effects of immunosuppressive drugs (drug therapy may alter the activity of drug 
metabolizing enzymes) 
Cyclosporine A has been reported to have hepatotropic effect during hepatic regeneration 
(Mazzaferro et al., 1990). Cyclosporine A infusion stimulated cell renewal significantly 
and restored hepatocyte size in the infused lobes with a dose-response relationship from 
0.6 mg/kg/day to 4 mg/kg/day in dogs (Mazzaferro et al., 1990). A study using male nude 
rats with T-cell deficiency showed that tacrolimus affected hepatic growth (DNA 
synthesis) by nonimmunoligical pathways (Francavilla et al., 1991). However, despite 
these reports indicating a tropic effect on the hepatic regeneration under 
immunosuppressive treatment, several studies have noticed that the liver weight 
restitution or liver growth was not affected by cyclosporine A during hepatic regeneration 
(Makowka et al., 1986; Kahn et al., 1990; Coughlin et al., 1987).  
 
Chronic treatment with cyclosporine A at high doses (15 mg/kg subcutaneous dosing 
daily) suppressed CYP3A protein expression and in vitro activity (Brunner et al., 1998). 
Tacrolimus seems to interfere predominantly with the CYP isoforms 2A, 2B, 2C and 3A 
in rats and with the CYP subtypes 1A, 2B, 2C and 3A in man (Lupp et al., 2003). On the 
other hand, in vitro incubation with T cells showed that both cyclosporine A (100 nM) 
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and tacrolimus (10 nM) suppressed the expression of IL-2, IL-3, IL-4, c-myc, and TNF α 
(Tocci et al., 1989). This may modulate the effects of cytokines on drug metabolizing 
enzymes during hepatic regeneration. Conversely, since only serum levels of IL-6 and 
three soluble cytokine receptors (TNF α receptor I and II, IL-6 receptor) were 
significantly increased during hepatic regeneration (Fulop et al., 2001), the suppression 
of TNF α and other ILs by cyclosporine A and tacrolimus may have no obvious effect on 
the expression or activity of drug metabolizing enzymes. It is not clear whether the 
indirect effect or direct effect of cyclosporine and tacrolimus will predominate in a 
regenerating rat liver.  
 
4. In vivo drug metabolism 
Liver plays an important role in the elimination of endogenous and exogenous agents 
such as drugs, hormones and other chemicals. Hepatic metabolism of drugs can be 
influenced by hepatic blood fow (Q), intrinsic ability of the liver to metabolize drugs 
(Clint) and the unbound fraction of the drug in blood (fu). In the eliminating organ, 
changes in blood flow will alter the clearance of drugs with a high extraction ratio (> 0.7, 
extraction ratio is calculated as total body clearance divided by blood or plasma flow), 
but will not alter the clearance of drugs with a low extraction ratio (< 0.2). Changes in fu 
or Clint will change the clearance of low clearance drugs, but will not affect the clearance 
of high clearance drugs. Clint (ml/min) is calculated as maximal velocity (Vm (mol/min)) 
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divided by Km (mol/ml). Due to the effect of cytokines and immunosuppressive drugs on 
drug metabolizing enzymes mentioned above, the activity of various drug metabolizing 
enzymes is likely to be changed during hepatic regeneration. Vm can be altered due to the 
altered activity of various drug metabolizing enzymes or the reduction in the mass of the 
eliminating organ. The unbound fraction of a drug in blood can be altered in certain 
disease states due to the change in the concentration of plasma proteins such as albumin 
and α-1-acid glycoprotein or the presence of competing endogenous chemicals such as a 
bilirubin and fatty acids. It has been reported that the concentration of albumin was 
decreased by 20%, 24 hours after hepatic regeneration and the concentration of 
alpha-1-acid glycoprotein was increased to 181%, 7 days after hepatic regeneration 
(Fouad et al., 1992). In summary, we can anticipate changes in Q, Clint, and fu during 
hepatic regeneration and consequently changes in the pharmacokinetics of drugs that are 
metabolized in the liver. 
 
5. Methods for studying drug metabolizing activity 
Generally two strategies have been used to study drug metabolism: in vitro and in vivo. In 
the in vivo method, a probe substrate is administered to the subject or animal and multiple 
blood or any relevant biological fluids are sampled during specific time points. Total 
body clearance (or AUC) is then calculated based on concentration-time profile. This 
approach gives a good prediction of the activity of drug metabolizing enzyme under the 
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following conditions: 1) the substrate should be absorbed completely (IV administration); 
and 2) almost 100% of drug is metabolized by the liver only and not eliminated through 
the renal route (almost no parent drug recovered in the urine). In vitro methods typically 
involve whole liver perfusion, liver slices, isolated hepatocytes, or subcellular fractions. 
In the present study, we have used both in vivo method and in vitro method (subcellular 
fraction) to evaluate the effect of hepatic regeneration on drug metabolism. 
 
Drug Therapy in LDLT Patients 
Liver transplant patients are often treated with several drugs. Transplant patients receive 
one or more immunosuppressive drugs, antibiotics, antiviral drugs, antifungal drugs and 
others. Remarkable advances in immunology and the discovery of more selective 
immunosuppressive drugs have contributed significantly to the decreased incidence of 
acute rejection. Introduction of cyclosporine in the early 1980s, the introduction of 
tacrolimus in the mid-1990s and the introduction of mycophenolic acid in combination 
with cyclosporine and prednisone in the late 1990s have markedly increased the graft and 
patient survival (Wiesner et al., 2003). Currently, with tacrolimus-based 
immunosuppressive regimens, chronic rejection has decreased to 5% (Wiesner et al., 
1999; Wiesner et al., 2003). Living donor liver transplant patients are normally treated 
with immunosuppressive drugs such as tacrolimus and mycophnolic acid. In addition, 
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acetaminophen is the most widely used analgesic in the USA and is sometimes used in 
the transplant patients for analgesia or fever reduction.  
 
1. Tacrolimus 
Tacrolimus (FK506, Prograf, Fujusawa, Osaka, Japan) is isolated from Streptomyces 
tsukubasensis and has a 23-member macrolide lactone structure (Figure 2).  
 
 
Figure 2. Chemical structure of tacrolimus. 
Tacrolimus is a potent immunosuppressive drug. The structures of nine metabolites of 
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tacrolimus generated by liver microsomes of different species have been identified 
(Iwasaki et al., 1993; Lhoest et al., 1993; Iwasaki et al., 1995). The reactions involved in 
the metabolism of tacrolimus include, hydroxylation at C(12), C(19), and the C(36) and 
C(37) vinyl group, as well as demethylation at C(13), C(15) and C(31) (Lampen et al., 
1995). Immunoinhibition with anti-CYP3A abolished the formation of almost all 
tacrolimus metabolites (Sattler et al., 1992). Subsequent study using liver microsome and 
cDNA expression system also documented that CYP3A is the major isoform involved in 
the metabolism of tacrolimus (Shiraga et al., 1994). Among the metabolites of tacrolimus, 
13-demethylated metabolite (M1) is the major metabolite and accounts for about 75% of 
total metabolites in rats (Perotti et al., 1994).  
 
Tacrolimus is metabolized extensively in rats, with limited excretion of the unchanged 
drug in the urine, bile or feces; biliary excretion is the major route of elimination of 
radioactively labeled drug and metabolites (Iwasaki et al., 1991). In humans, currently, 
most of the pharmacokinetic data available on tacrolimus are based on an enzyme-linked 
immunosorbent assay method. The rate of absorption of tacrolimus is variable with peak 
blood or plasma concentrations being reached in 0.5 to 6 hours. Approximately 25% of 
the oral dose of tacrolimus is bioavailable (Venkataramanan et al., 1995). Tacrolimus is 
extensively bound to red blood cells, with a mean blood to plasma ratio of about 15. 
Albumin and alpha 1-acid glycoprotein appear to primarily bind tacrolimus in plasma 
(Venkataramanan et al., 1995). Less than 0.5% of unchanged drug was detectable in feces 
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and urine (Moller et al., 1999). The mean disposition half-life is 12 hours and the total 
body clearance based on blood concentration is approximately 0.06 L/h/kg 
(Venkataramanan et al., 1995). The volume of distribution is within the range of 221 to 
565 L (Staatz and Tett, 2002). The elimination of tacrolimus is decreased in the presence 
of liver impairment and in the presence of several drugs (Venkataramanan et al., 1995). 
Due to the interpatient and intrapatient variability in the pharmacokinetics and the narrow 
therapeutic index, monitoring of the trough concentration of tacrolimus is necessary to 
optimize dosing requirements. 
 
The pharmacokinetic properties of tacrolimus have not been completely characterized in 
living related liver transplant patients and the clinical experience in adult living donor 
liver transplantation is limited. A recent population pharmacokinetic study (daily single 
blood sampling for each patient) demonstrated that the rate of metabolism of tacrolimus 
was quite different in recipients of partial liver grafts (Fukatsu et al., 2001). The use of 
reduced dose of tacrolimus in LDLT patients indicates that the clearance of tacrolimus is 
lower during the initial postoperative period in these patients (Fukatsu et al., 2001; 
Trotter et al., 2002; Harihara et al., 2000; Troisi et al., 2002). Another study showed that 
adult living donor liver transplant patients receiving the right lobe required 50% less 
tacrolimus during the first 2 weeks postoperatively as compared with cadaveric liver 
recipients (Morgan et al., 2001; Troisi et al., 2002). This requirement is probably due to 
the reduced early postoperative hepatic function and the concomitant postoperative 
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metabolic overload (Fukatsu et al., 2001; Troisi et al., 2002). The pharmacokinetics of 
tacrolimus has not been completely characterized in LDLT patients.  
 
2. Mycophenolic acid 
Mycophenolic acid (Figure 3) (MPA, the active compound of the prodrug mycophenolate 
mofetil (MMF, CellCept, Roche, Nutley, NJ), an uncompetitive, selective and reversible 
inhibitor of inosine monophosphate dehydrogenase (IMPDH), is used for 
immunosuppressive therapy after transplantation. MPA is primarily metabolized to 
7-O-glucuronide (MPAG) in the body. 
 
           Figure 3. Chemical structure of mycophenolic acid. 
 
Initially, UGT1A8, 1A9 and 1A10 were thought to be responsible for the formation of 
MPAG (Mackenzie, 2000). Since UGT1A8 and UGT1A10 were only found in the 
gastrointestinal tract (Mojarrabi and Mackenzie, 1998), MPA is thought to be the probe 
substrate for UGT1A9 in human livers. Subsequently, a study conducted using cDNA 
expressed UGTs showed that almost all human UGT1A and 2B are capable of  
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metabolizing MPA to MPAG (Shipkova et al., 2001). The most recent report clearly 
shows that UGT 1A9 is the main isoform involved, with at least 55% contribution to the 
hepatic MPAG production. UGT 1A1 and 1A6 probably account for a part of MPAG 
production in the liver, whereas UGT 1A7, 1A8, and 1A10 which are expressed in the 
small intestine, could contribute to the intestinal first-pass of MPA (Picard et al., 2005). 
 
Over 95% of the administered dose is eventually excreted as MPAG in humans 
(Bullingham et al., 1996b; Morissette et al., 2001). A negligible amount of the drug is 
excreted as MPA (<1% of dose) in 48-hour urine (Bullingham et al., 1996a). When MPA 
was administered intravenously to Wistar or Sprague-Dawley rats, about 26% of the dose 
was excreted in the bile, suggesting that the biliary excretion of MPAG is extensive in 
these rat strains (Kobayashi et al., 2004) even though the glucuronide is preferentially 
excreted into the urine (about 70% of dose) in humans (Bullingham et al., 1996a). 
Mutidrug resistant protein 2 (Mrp2), an efflux transporter located on the apical side of 
hepatocytes, has been shown to be essential for the biliary excretion of MPAG based on 
studies in Mrp2 deficinent rats (Eisai hyperbilirubinemic rats) (Kobayashi et al., 2004). 
Mrp3, an uptake transporter located on the basolateral side of hepatocyte, is also capable 
of transporting several glucuronide conjugates (Hirohashi et al., 1999). It is likely that 
Mrp3 can efficiently transport MPAG across the sinusoidal membrane and back into the 
blood (Kobayashi et al., 2004). After biliary excretion, MPAG is either eliminated in the 
feces or is hydrolyzed to MPA by β-glucuronidases in the gut and is reabsorbed. 
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Mycophenolic acid repeatedly undergoes glucuronidation and Mrp2-mediated biliary 
excretion in the liver and deglucuronidation and subsequent intestinal reabsorption in the 
intestine until MPA molecules are finally excreted to the urine as MPAG (Kobayashi et 
al., 2004). At clinically relevant concentrations, MPA and MPAG are about 97% and 82% 
bound to albumin, respectively (Bullingham et al., 1998).  
 
3. Acetaminophen 
Acetaminophen (Figure 4) is primarily metabolized to glucuronide and sulfate conjugate 
by UGT and sulfonyltransferase (SULT). There is a cytochrome P450-catalyzed 
oxidative pathway of APAP metabolism, forming a reactive quinine form, 
N-acetyl-p-benzoquinone imine (NAPQI) (Figure 4) 
 
      acetaminophen           NAPQI 
Figure 4. Chemical structure of acetaminophen and NAPQI. 
 
CYP3A and 2E1 have been reported to contribute to the formation of NAPQI in human 
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liver microsomes (Thummel et al., 1993). However, the Km (4.4 mM) for CYP2E1 was 
25 times higher than Km (0.28 mM) for CYP3A4. The in vitro human liver microsomal 
inhibition data showed that CYP3A4 was, at most, a minor contributor to the formation 
of NAPQI (10%) at therapeutically relevant concentrations of APAP (0.1 mM) (Thummel 
et al., 1993). NAPQI can be further metabolized to its sequential metabolites: 
glutathione-, Cys- and NAC- (mercapturate-) conjugates. 
 
After single dose, plasma acetaminophen concentrations in rats declined exponentially, 
with a half life that increased with increasing doses (Galinsky and Levy, 1981), indicating 
a non-linear pharmacokinetics in rats. The fraction of the dose that was converted to 
acetaminophen sulfate decreased with increasing doses (Jollow et al., 1974; Galinsky and 
Levy, 1981). Both acetaminophen glucuronide and acetaminophen sulfate formation in 
rats are capacity-limited, just as in humans (Levy and Yamada, 1971; Slattery and Levy, 
1979; Galinsky and Levy, 1981). 
 
A majority of the drugs used in LDLT patients are primarily eliminated by hepatic 
metabolism (Table 1). Therefore a thorough knowledge of hepatic metabolizing capacity 
in LDLT patients is of importance in optimizing drug therapy in this patient population. 
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Table 1. Common used drugs in transplantation. 
Drug class Drug Major elimination route 
Immunosuppressive drugs Prednisone  Liver 
 Cyclosporine A Liver 
 Tacrolimus Liver 
 Sirolimus Liver 
 Mycophenolic acid Liver 
Antibiotics Trimethprim Kidney 
 Acyclovir Kidney 
 Ganciclovir Kidney 
Antifungal drugs Itraconazole Liver 
 Ketoconazole Liver 
 Fluconazole Liver 
 Voriconazole Liver 
Antihypentensive drugs Diltiazam Liver 
 Nifedipine Liver 
 
Central Hypothesis 
Liver resection will produce a reduction in the in vitro hepatic functional activity via 
decreased expression of different drug metabolizing enzymes mediated by the acute 
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phase cytokines such as Il-6 and TNF-α. This in combination with a reduced liver mass 
will result in decreased clearance of drugs that are metabolized in the liver to a magnitude 
that is much greater than the loss of liver mass. Immunosuppressive drugs that are 
routinely used in liver transplant patient will increase activity of various metabolizing 
enzymes due to their effect on cytokines and their hepatotropic effect. 
 
Hypothesis 1 (Chapter 2) 
We hypothesize that the hepatic expression and in vitro activity of CYP3A will be 
impaired during the initial phase of hepatic regeneration due to the cytokines that 
are released, but will recover over time as the cytokine levels return to normal. We 
also hypothesize that treatment with cyclosporine A and tacrolimus will prevent the 
reduction in the expression or activity of CYP3A during hepatic regeneration due to 
their effect on proinflammatory cytokines and their hepatotropic effect. Partial 
hepatectomy will be performed in male Sprague-Dawley rats to induce hepatic 
regeneration since female Sprague-Dawley rats lack the expression of CYP3A or express 
it at very low levels. The mRNA expression, protein expression and in vitro activity of 
CYP3A will be measured using real-time PCR, western blot and liver microsomal 
incubations with probe substrate, testosterone, respectively. Effects of cyclosporine A and 
tacrolimus on the in vitro activity of CYP3A will also be evaluated at different time 
points during hepatic regeneration. 
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Hypothesis 2 (Chapter 3) 
We hypothesize that the hepatic intrinsic clearance of tacrolimus, a substrate of 
CYP3A enzyme will be impaired and the clearance of tacrolimus will be significantly 
reduced during hepatic regeneration and the magnitude of reduction will be related 
to the reduction in the activity measured in vitro and the reduction in liver mass. 
Partial hepatectomy will be performed in male Sprague-Dawley rats to initiate hepatic 
regeneration. In vitro metabolism of tacrolimus will be assessed in liver microsomes 
based on the formation of 13-demethylated tacrolimus. Pharmacokinetics of tacrolimus 
after IV administration will be assessed at different time points during hepatic 
regeneration.   
 
Hypothesis 3 (Chapter 4) 
We hypothesize that the hepatic expression and in vitro activity of various forms of 
UGT will be decreased during the initial phase of hepatic regeneration due to 
decreased expression of transcription factors involved in their regulation as a result 
of increased levels of cytokines such as IL-6 and TNF-α, but will recover completely 
over time. Partial hepatectomy will be performed in male Sprague-Dawley rats to initiate 
hepatic regeneration. The mRNA expression (UGT1A1, 1A2, 1A3, 1A5, 1A6, 1A7, 1A8, 
2B1, 2B2, 2B3, 2B6, 2B8, and 2B12) and in vitro activity (UGT1A1, 1A6/7, 2B1, 
2B1/3/6, 2B2 and 2B12) of different UGTs will be measured using specific primers and 
specific substrates, respectively, at different time points during hepatic regeneration. 
 26
Expression of some of the transcription factors such as CAR, PXR, HNF-1, C/EBP α will 
also be evaluated. 
 
Hypothesis 4 (Chapter 5) 
We hypothesize that the hepatic intrinsic clearance of mycophenolic acid, a 
substrate for several UGTs, will be decreased and the clearance of mycophenolic 
acid will be significantly decreased during hepatic regeneration and the magnitude 
of reduction in clearance will be related to the reduction in UGT in vitro and the loss 
of liver mass. We also hypothesize that the clearance of MPAG will be significantly 
reduced due to the reduction in liver mass and correspondingly decreased total 
activity of transporters in the liver during hepatic regeneration. Partial hepatectomy 
will be performed in male Sprague-Dawley rats to initiate hepatic regeneration. In vitro 
metabolism of mycophenolic acid will be assessed in liver microsomes based on the 
formation of mycophenlic acid glucuronide. Pharmacokinetics of mycophenolic acid 
(UGT substrate) and its metabolite, mycophenolic acid glucuronide, will be evaluated at 
different time points during hepatic regeneration. The protein and mRNA expression of 
related drug transporters such as multidrug resistance associated protein (Mrp) 2 and Mrp 
3 will be also measured at different time points during hepatic regeneration. 
 
Hypothesis 5 (Chapter 6) 
We hypothesize that the in vivo metabolism of acetaminophen will be altered during 
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hepatic regeneration with increased formation of NAPQI related toxic metabolite 
and APAP glucuronide and decreased formation of APAP sulfate due to the 
dose-dependent pharmacokinetics of APAP. Partial hepatectomy will be performed in 
male Sprague-Dawley rats to initiate hepatic regeneration. Twenty four-hour urine will be 
collected to measure various metabolites of acetaminophen with different doses at 
different time points during hepatic regeneration. 
 
Hypothesis 6 (Chapter 2, 3, 4, 5, 6) 
We hypothesize that the liver mass will recover to normal with time after partial 
hepatectomy. With a full recovery in liver mass and normalization of cytokine levels 
such as IL-6 and TNF-α, the activity of CYP3A, UGTs and clearance of tacrolimus 
and MPA and metabolism of APAP will recover to normal. 
 
The studies proposed in this document will significantly increase our understanding of 
the pharmacokinetics of drugs during hepatic regeneration. Information gained from these 
studies will help us in designing future studies to optimize drug therapy in LDLT patients. 
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Chapter 2 Impaired Activity and Expression of CYP3A during Hepatic 
Regeneration in Rats 
 
Abstract 
Objective Hepatic regeneration is very critical to the success of living donor liver 
transplantation, which allows a reduced size liver to grow in size to accommodate the 
requirements of both the donor and the recipient. The objectives of this study were to 
evaluate 1) the activity and protein and mRNA expression of hepatic cytochrome P450 
(CYP) 3A and 2) the effect of cyclosporine A and tacrolimus on the activity of hepatic 
CYP3A in rats at various time points after initiation of hepatic regeneration by partial 
hepatectomy (PHx).  
Methods The activity of CYP3A was determined by the formation rate of 
6β-hydroxytestosterone in liver microsomes incubated with the saturating concentration 
(200 µM) of testosterone. The protein expression of CYP3A was evaluated using Western 
blotting. The mRNA expression of CYP3A was detected by quantitative Real-time PCR. 
The effect of cyclosporine A and tacrolimus on CYP3A activity was studied by oral 
administration of cyclosporine A and tacrolimus immediately after PHx at a daily dose of 
10 mg/kg, bid; and 2 mg/kg, bid, respectively for 24 hours, 6 days and 14 days.  
Results The hepatic CYP3A activity, protein and mRNA expression were significantly 
decreased at 24 hours and day 6, but recovered back to normal by day 14. Cyclosporine A 
and tacrolimus didn’t have any additional effect on the activity of CYP3A or on the 
recovery of CYP3A activity.  
Conclusions During hepatic regeneration, the hepatic CYP3A was impaired transiently 
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but recovered completely with time. In spite of incomplete recovery of liver mass by day 
18, the functional capacity of the liver returned to normal in the liver donors. 
Cyclosporine A and tacrolimus did not have any effect on hepatic CYP3A activity during 
hepatic regeneration. These results indicate that the clearance of CYP3A substrates will 
be transiently decreased in the LDLT patients, but will completely recover to normal with 
time. Reduction in doses of drugs that are metabolized by CYP3A are required during the 
first few weeks after transplantation. Further, hepatic regeneration, as determined by the 
activity of CYP3A, will proceed normally in presence of immunosuppressive drug 
therapy with cyclosporine A and tacrolimus. 
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Introduction 
Liver transplantation is an accepted life-saving therapy for patients with end-stage liver 
diseases. The number of patients who need liver transplantation has increased 10-fold in 
the recent years, but the number of cadaveric organs that are available has been stagnant. 
In the year 2000, only about 25% of the 15,000 patients in the transplant waiting list 
received a donor organ. Nearly 1800 patients died while waiting for a liver (Wiesner et al., 
2003). Living donor liver transplantation (LDLT) has emerged as an effective therapy for 
some selected patients and is a partial solution to the current severe shortage of cadaveric 
donor organs (Seaman et al., 2001). The number of LDLTs performed in the US has 
increased from less than 100 in the year 1998 to more than 500 in the year 2001 (Wiesner 
et al., 2003).
 
In LDLT, removal of the right hepatic lobe has become the preferred donor procedure 
(Wachs et al., 1998; Hayashi and Trotter, 2002). After surgery, the donor and recipient 
have a small liver that grows in size to accommodate the requirements of the donor and 
recipient, respectively due to hepatic regeneration. Liver regeneration after partial 
hepatectomy (PHx) involves proliferation of all the existing mature cellular populations, 
including hepatocytes, biliary epithelial cells, fenestrated endothelial cells, kupffer cells, 
and cells of Ito (Michalopoulos and DeFrances, 1997). Many genes such as c-fos, c-jun, 
c-myc, bclx, p53, p21, mdm2, cyclin D1, E, C and B are also activated during hepatic 
regeneration (Fausto, 2000). Hepatic regeneration is believed to be triggered or activated 
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by hepatocyte growth factor (HGF) (Lindroos et al., 1991), transforming growth factor-α 
(TGF-α) (Mead and Fausto, 1989), tumor necrosis factor-α (TNF- α) (Diehl et al., 1994) 
and interleukin-6 (IL-6) (Matsunami et al., 1992). Elevated concentrations of HGF and 
IL-6 are observed in plasma after PHx (Lindroos et al., 1991; Matsunami et al., 1992; 
Fulop et al., 2001; Iwai et al., 2001). Several cytokines that are known to be up-regulated 
during hepatic regeneration are known to alter the activity of some of the hepatic drug 
metabolizing enzymes (Chen et al., 1995; Monshouwer et al., 1996; Abdel-Razzak et al., 
1993).    
 
Cytochrome P450 3A plays a significant role in the metabolism of approximately 50% of 
the drugs in use including several immunosuppressive drugs used in liver transplant 
patients such as cyclosporine A, tacrolimus, and sirolimus (Combalbert et al., 1989; 
Bertault-Peres et al., 1987; Vincent et al., 1992; Sattler et al; 1992). The regulation of 
CYP3A activity during hepatic regeneration in LDLT patients is particularly important. 
Even though the rate of hepatic regeneration may be different between the donor and the 
recipient in LDLT program with the donor requiring more regeneration (60% liver 
regeneration for the donor and 40% liver regeneration for the recipient), both the donor 
and the recipient require hepatic regeneration to restore the liver size. Since cyclosporine 
A and tacrolimus have been reported to be hepatotropic during hepatic regeneration in 
cell renewal and DNA synthesis (Mazzaferro et al., 1990; Francavilla et al., 1991), 
treating donors in LDLT with cyclosporine A and tacrolimus may be beneficial in 
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accelerating the recovery of impaired drug metabolizing activity. On the other hand, 
recipients normally receive immunosuppressive drugs during the process of hepatic 
regeneration after transplantation, which may directly affect the drug metabolizing ability 
of these patients. Limited data based on systemic studies of the regulation of CYP3A 
activity, protein and mRNA expression levels during hepatic regeneration exist and 
nothing is known about the effect of immunosuppressive drugs such as cyclosporine A 
and tacrolimus on the hepatic CYP3A activity and expression during hepatic regeneration. 
A thorough understanding of the alterations in the activity and expression of CYP3A 
during hepatic regeneration and the effect of immunosuppressive drugs on the activity of 
CYP3A is important to optimize drug therapy in LDLT patients. 
 
In this study, we have utilized partially hepatectomized rats to study the effect of hepatic 
regeneration and chronic treatment with cyclosporine A and tacrolimus on the in vitro 
activity, protein and mRNA expression of CYP3A enzyme. We hypothesized that the 
activity, protein content and mRNA expression of CYP3A will be decreased during the 
initial phase of heptic regeneration due to the increased concentration of IL-6 and that 
treatment with cyclosporine A and tacrolimus will prevent the reduction in the activity of 
CYP3A enzyme during hepatic regeneration due to their effect on proinflammatory 
cytokines and the hepatotropic effect on DNA synthesis. 
 
Materials and Methods 
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Chemicals 
Testosterone and 6β-hydroxytestosterone were purchased from Steraloids Inc. (Newport, 
RI). Cyclosporine A injection (250 mg/5 ml) (Lot No. 380518) was purchased from Ben 
Venue Labs (Bedford, OH). Tacrolimus, 10 mg/ml tacrolimus injection (Lot No. 
711337K), was a generous gift from Fujisawa Pharmaceutical Company (Osaka, Japan). 
CYP3A monoclonal antibody raised in mouse was obtained from BD Gentest (Woburn, 
MA). Horseradish peroxidase-conjugated sheep anti-mouse IgG was purchased from 
Amersham Biosciences, (Piscataway, NJ). Western Chemiluminescence reagent was 
bought from PerkinElmer Life Sciences, Inc. (Boston, MA). Reagents for reverse 
transcription were purchased from Promega (Madison, WI). Forward and reverse primers 
for CYP3A, beta-actin and beta-2-microglobulin (beta-2-m) were synthesized by Applied 
Biosystems (Forest city, CA). Rat IL-6 and TNF α kits were purchased from Pierce 
Biotechnology, Inc. (Rockford, IL). All other chemicals were purchased from Sigma 
Chemical Co. (St. Louis, MO). All solvents used were of HPLC grade. 
 
Animals 
The study protocol was approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of Pittsburgh. Partial hepatectomy was performed according 
to the method of Higgins and Anderson (1931). Male Sprague-Dawley rats weighing 
225-250 g were anesthetized with methoxyflurane inhalation and the ventral surface was 
shaved along the mid line and swabbed with betadine. A midline incision of 3-4 cm was 
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made. Blood vessels supplying the medial and left lateral lobes of the liver were sutured 
and these lobes were excised. This resulted in the removal of 65-75% of the total liver, 
leaving the right lateral lobe and the small caudate lobe. For the sham operation (served 
as paired controls), the liver was manipulated similar to the partial hepatectomy 
procedure, but was not excised. After surgery, the rats had free access to food and water 
and were maintained on a 12-hour light and 12-hour night cycle. Rats were sacrificed by 
CO2 inhalation at 24 hours, day 6 or day 14 after PHx. On the day of sacrifice, the livers 
from rats were perfused with ice-cold 0.15 M KCl, frozen in liquid nitrogen immediately 
and stored at -80ºC for extraction of total RNA and preparation of microsomes. In order 
to minimize the variability, all rats for each time points were ordered on the same day. 
Twelve rats were ordered every time (6 rats for PHx; 6 rats for sham) and the surgery was 
conducted between 9:00 am and 11:00 am. For the rats that were sacrificed at 24 hours, 3 
ml blood were collected at the time of sacrifice. The whole blood was centrifuge 
immediately after collection at 3,000 rpm for 10 minutes and the serum was stored at 
-20ºC for cytokines measurement. 
 
Liver Mass 
The liver mass (L.M.) recovery was calculated in the following way: Wet weight of the 
remaining liver lobes after PHx / Estimated total L.M. (calculated by multiplying B.W. at 
the time of sacrifice X ratio of L.M. to B.W for normal rats). Here the ratio of L.M. to 
B.W. of 0.04 was used for normal rats (Davies and Morris, 1993). 
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 Microsome Preparation 
Liver microsomes were prepared by a differential centrifugation procedure. All 
instruments and buffers were kept on ice during this procedure. The whole liver lobe was 
used to prepare microsomes to avoid the possibility of uneven distribution of CYP3A. 
The CYP3A activity among different lobes from the same rat (N = 5 rats) was also 
evaluated. There was no difference in the CYP3A activity between the two different lobes 
(1.36 ± 0.20 vs 1.23 ± 0.17 nmol/mg protein/min, P > 0.5, paired t-test). Liver samples 
were placed in 3-4X their weight of homogenization buffer (50 mM Tris HCl buffer, 1.0 
% KCl and 1 mM EDTA, pH 7.4) and homogenized using an electrical homogenizer. This 
homogenate was then centrifugated at 10,000 g for 20 min at 4ºC. Supernatants were then 
centrifuged at 105,000 g for 65 min at 4ºC. The pellets were reconstituted using a manual 
homogenizer in 2X their weight of a Tris HCl buffer (50 mM Tris HCl buffer, pH 7.4) 
containing 20% glycerol. Microsomes were aliquoted and stored at -80ºC until used in 
incubation studies (It has been shown that the activity of microsomal protein didn’t 
change significantly with ten freeze/thaw cycles, Pearce et al., 1996). The protein content 
was determined by Lowry’s method with bovine serum albumin as the standard (Lowry et 
al., 1951). Standards (200 µl) in triplicate and diluted samples (200 µl) in duplicate were 
mixed with alkine copper sulphate solution (2.5 ml). Then, Folin reagent (250 µl) was 
added to each tube and the samples were maintained for 45 min at room temperature. The 
absorbance was measured at 490 nm with a 96 well plate reader. 
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 IL-6 and TNF-α measurement 
For IL-6 and TNF-α measurement, fifty µl of pre-treatment buffer to each well followed 
by adding 50 µl of standards and samples. The plate was covered and incubated at room 
temperature for 2 hours (1 hour for TNF-α measurement). After incubation, the plate was 
washed three times. One hundred µl of biotinylated antibody reagent (50 µl for TNF-α 
measurement) was added to each well after washing. The plate was then covered and 
incubated at room temperature for 1 hour again. After washing the plate for three times, 
one hundred µl of prepared streptavidin-HRP solution was added to each well. After 
incubating for 30 min, the plate was washed for three times. Then 100 µl of premixed 
TMB substrate solution was added to each well. The plate was developed in the dark at 
room temperature for 30 min (10 min for TNF-α measurement). After development, the 
reaction was stopped by adding 100 µl of stop solution to each well. The absorbance was 
measured on a plate reader at 440 nm minus 540 nm. 
 
Microsome Incubation with Testosterone 
The formation of 6β-hydroxytestosterone from testosterone was used as a marker of 
CYP3A activity. The incubation was carried out in a glass culture tube containing a 
saturating concentration of testosterone (200 µM) for activity measurement and a series 
of concentrations of testosterone (0-250 µM) for Km determination, 0.5 mg/ml 
microsomal protein (linear to 0.5 mg/ml, Figure 5) and 10 mM MgCl2, with the fluid 
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volume being adjusted to 0.5 ml by the addition of 100 mM phosphate buffer (pH 7.4). 
The tubes were pre-incubated for 10 minutes at 37ºC in an oscillating water bath and 
then one mM β-NADPH was added to initiate the reaction. After incubation for 10 
minutes (linear to 20 min, Figure 6), the reaction was stopped by adding an equal volume 
(0.5 ml) of ice-cold methanol. The reaction mixture was transferred to a fresh eppendorf 
tube and the tube was then centrifuged at 13,000 rpm for 5 minutes. The supernatant was 
analyzed for 6β-hydroxytestosterone using a HPLC method. 
 
Figure 5. Relationship between microsomal protein concentration and the amount of 
6β-hydroxytestosterone formed in rat liver microsomes. Concentration of testosterone: 
200 µM; incubation time: 10 min. 
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 Figure 6. Relationship between time of incubation and the amount of 
6β-hydroxytestosterone formed in rat liver microsomes. Concentration of testosterone: 
200 µM; microsomal protein concentration: 0.5 mg/ml. 
 
HPLC Analysis of 6β-hydroxytestosterone 
6β-hydroxytestosterone was measured by the method developed in our laboratory 
(Kostrubsky et al., 1999). More specifically, one hundred µl of the incubation solution 
was injected onto a LiChrospher 100 RP-18 column (250 mm x 4.6mm, 5 µ) heated to 
30ºC. A mobile phase of methanol/water (60/40) was used at a flow rate of 1.2 ml/min. 
The UV detector was set at 242 nm. The retention time for 6β-hydroxytestosterone was 
about 4.9 minutes and the total run time was 20 minutes. The standard curve was linear 
over the concentration of 0.25-5 µg/ml. The intra- and inter-day CV(%) at 0.25 µg/ml and 
5 µg/ml was less than 3% (n =6). 
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Western blot 
Microsomal proteins (20 µg/lane) were electrophoretically resolved using 10% Bio-Rad 
Ready gels and then transblotted for 3 hours at 4°C onto PVDF (polyvinylidene difluoride) 
membrane (Millipore, Billerica, MA) with Tris-glycine buffer containing 20% methanol 
and 0.1% SDS. The blots were then blocked for 1 hour in 5% blocking grade nonfat dry 
milk (Bio-Rad, Hercules, CA) in TBS-Tween buffer (15 mM Trizma base, 154 mM 
sodium chloride, 0.05% Tween 20, pH 7.4) at room temperature, incubated for 2 hours at 
room temperature with mouse anti-CYP3A monoclonal antibodies diluted in 0.5% nonfat 
dry milk (1:1000), and then washed three times for 15, 5 and 5 min, respectively, in 
TBS-Tween buffer. After the above washes, the blots were incubated for 1 h at room 
temperature with sheep anti-mouse IgG conjugated with horseradish peroxidase 
(Amersham Biosciences Inc., Piscataway, NJ), diluted 1:10,000 in TBS-Tween buffer, and 
then subjected to three additional washes (15, 5, and 5 min respectively). CYP3A 
protein-antibody complexes were detected with ECL Western blotting reagents.  
 
Extraction of RNA and Reverse Transcription   
Total RNA was extracted from 50-100 mg livers with 1 ml Trizol (Invitrogen, Carlsbad, 
CA) according to the instructions of the manufacturer. Extracted RNA was quantified 
spectrophotometrically at 260/280 nm and the integrity was checked using agarose gel. 
After removal of DNA using RNase-Free DNase, 2 µg of RNA was reversely transcribed 
using 0.5 µg of random hexamer (Promega, Madison, WI) heated to 70ºC for 5 minutes, 
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and then cooled to 4ºC. A reaction mixture containing 200 U Moloney murine leukemia 
virus reverse transcriptase, 1 mM dNTPs and 25 U RNasin (Promega, Madison, WI) was 
added to the previous mixture and incubated at 37ºC for 60 minutes. The resulting cDNA 
was diluted 10 folds and stored at -20ºC. The control samples were also prepared with the 
same procedure by replacing the reverse transcriptase with water (negative controls). 
 
Real-Time PCR  
Polymerase chain reaction (PCR) was performed on Applied Biosystems 7700 cycler 
using 5 µl of cDNA, 7.25 pmol of forward and reverse primers and 12.5 µl of SYBR 
Green PCR Master Mix (Applied Biosystems, Foster City, CA) for a total volume of 25 
µl. Forward and reverse primers, designed using Primer Express 2.0 (Applied 
Biosystems), are 5’-TCAAGGAGATGTTCCCCATCA-3’ (Forward), 
5’-TCTCCGCCTCTTGCTTCAA-3’ (Reverse) for rat CYP3A; 
5’-CTGGCCTCACTGTCCACCTT-3’ (Forward), 5’-GGGCCGGACTCATCGTACT-3’ 
(Reverse) for β-actin and 5’-CGTGCTTGCCATTCAGAAAA-3’ (Forward), 
5’-GAAGTTGGGCTTCCCATTCTC-3’ for beta-2-m. The nucleotide-nucleotide Blast 
has confirmed that there was no match between the primers and the rat genome except for 
the target genes. Cycling conditions were 1 cycle at 95ºC for 10 min, followed by 50 
cycles with 15 s at 95°C and 1 min at 60°C. The relative cDNA content was determined in 
duplicate using standard curves created from cDNA and normalized to beta-2-m for each 
sample. For each pair of primers, the control without reverse transcriptase was also used 
 41
for PCR reactions in duplicate to confirm that there was no genomic DNA contamination 
in the cDNA samples. 
 
Data Analysis 
All data are reported as mean ± SD. Student’s t-test was used to evaluate the differences 
between the activities in the regenerating lobes and the lobes from sham group at a 
significant level of P < 0.05. Comparisons among groups were made via a one way 
analysis of variance (P < 0.05). For sample size calculation, the initial formation rate of 
6β-hydroxytestosterone from the lobes of sham (24 hours) (1.72 ± 0.22 nmol/mg 
protein/min), was used. With a power of 80% and α = 0.05, to detect a 25% difference, 4 
rats were required. Experiments were completed with 4 to 6 rats in each group. 
 
Results 
Recovery of Liver Mass during Hepatic Regeneration. 
Liver mass recovery after initiation of hepatic regeneration with or without cyclosporine 
A or tacrolimus administration is illustrated in Figure 7. Liver mass was 31.3 ± 2.0% at 
24-hours, 50.5 ± 4.0% on day 6 and 72.3 ± 5.1% on day 14. The recovery of liver mass 
approached a plateau by day 18. Cyclosporine A or tacrolimus did not have any effect on 
the recovery of liver mass. 
 
Serum concentration of IL-6 and TNF-α   
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The serum concentration of IL-6 was signicantly increased 24 hours after hepatic 
regeneration (PHx-24 hour vs. Sham: 124 ± 28 pg/ml vs. 47 ± 18 pg/ml, P < .01, 
student’s t-test). However, the serum concentration of TNF-α was not altered 24 hours 
after initiation of hepatic regeneration (PHx-24 hour vs. Sham: 89 ± 20 pg/ml vs. 95 ± 18 
pg/ml, P > .05, student’s t-test). 
 
In Vitro Activity of CYP3A as Measured by the Formation of 6β-hydroxytestosterone 
from Testosterone 
Figure 8 shows the activity of CYP3A enzyme during hepatic regeneration. CYP3A 
activity decreased significantly at the 24th hour compared to the activity in the sham 
group (t-test, P < .01, Figure 8) and didn’t significantly differ between day 6 and 24 
hours. The activity eventually returned to normal level by day 14 (t-test, P > .05, Figure 
8). No significant difference in Km was observed at 24-hour or 14 days of hepatic 
regeneration compared to corresponding control values (24-hour: 34.7 ± 12.0 vs. 25.2 ± 
7.7 µM; 14-day: 26.0 ± 8.7 vs. 28.0 ± 5.1 µM; t-test, P > .05). 
 
Immunochemistry of CYP3A 
The results of the western blot for CYP3A are shown in Figure 9. The regenerating lobes 
had a lower CYP3A protein at 24 hours and 6 days. The protein expression recovered 
almost completely by day 14. 
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Selection of Control Genes 
The mRNA expressions of beta-actin and beta-2-m at different time points during hepatic 
regeneration are shown in Figure 10. The mRNA expression of beta-actin almost doubled 
at 24 hours (sham vs. PHx: 0.19 ± 0.03 vs. 0.32 ± 0.06, P < .01). The mRNA level of 
beta-actin in the PHx group was similar to the paired sham group by day six. The mRNA 
expression of beta-2-m, on the other hand was relative stable during hepatic regeneration 
and was not significantly different between paired sham groups and PHx groups. 
Therefore, beta-2-m was chosen as the normalization gene for the study of other target 
genes. 
 
mRNA Expression of CYP3A  
The mRNA expression of CYP3A after initiation of regeneration is shown in Figure 11. 
The mRNA expression of CYP3A was decreased to about 20% of control value in paired 
sham group by twenty four hours (t-test, P < .01). The mRNA expression of CYP3A 
stayed at the same level on day 6 (t-test, P > .05), and was lower than control level in 
paired sham group (t-test, P < .05). After regeneration for 14 days, the mRNA expression 
returned to control level (t-test, P > .05).  
 
Effect o  Tacrolimus and Cyclosporine f
Twenty fours hours, six days and fourteen days of oral administration of cyclosporine A 
and tacrolimus didn’t have any effect on the recovery of CYP3A activity (Figure 12). 
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 Figure 7. Recovery of liver mass during hepatic regeneration. The liver mass 
recovery was represented as percentage in the following way: Wet weight of the 
remaining liver lobes after PHx/Estimated total liver mass (calculated by multiplying 
body weight at the time of sacrificing X ratio of liver mass to body weight for normal 
rats). Here the ratio of liver mass to body weight for a normal rat was assumed to be 0.04. 
N = 5 to 6 rats. 
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 Figure 8. CYP3A activity at different time points during hepatic regeneration. 
Sham: liver lobes from sham groups; PHx: regenerated liver lobes after PHx. The activity 
was measured using 6β-hydroxytestosterone formation rate at saturating testosterone 
concentration (200 uM). ** P < .01 vs. sham (student’s t-test). N = 4 to 6 rats. 
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 Figure 9. Immunochemical analysis of the CYP3A protein expression at different 
time points after initiation of regeneration. Equal amounts of microsomal protein were 
loaded in each lane. Sham: pooled lobes from sham groups; PHx: pooled regenerated 
lobes after PHx. Microsomal proteins from 6 rats were pooled together in each group. 
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 Figure 10. The mRNA expression of control genes at different time points after 
initiation of regeneration. Panel A: beta-actin; Panel B: beta-2-microglobulin. Sham: 
pooled lobes from sham groups; PHx: pooled regenerated lobes after PHx. The arbitrary 
mRNA values were determined by real time PCR as described in the Methods using 
pooled cDNAs generated from total RNAs from 6 normal livers as the standard. All data 
are expressed as mean ± SD. ** P < .01 vs. sham N = 4 rats. 
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 Figure 11. The mRNA expression of CYP3A at different time points after initiation 
of regeneration. Sham: pooled lobes from sham groups; PHx: pooled regenerated lobes 
after PHx. The relative mRNA level was determined by real time PCR as described in the 
Methods using pooled cDNAs generated from total RNAs from 6 normal livers as the 
standard. The arbitrary mRNA values were normalized with their respective beta-2-m 
values. ** P < .01 vs. sham (student’s t-test). N = 4 to 5 rats. 
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 Figure 12. Effect of drug treatments on CYP3A activity during hepatic 
regeneration. PHx: regenerated liver lobes after PHx; Cys A: cyclosporine A (10 
mg/kg/day, bid, po); tacrolimus: tacrolimus (2 mg/kg/day, bid, po). The activity was 
measured using 6β-hydroxytestosterone formation rate under saturating testosterone 
concentration (200 uM). P > .05, one-way ANOVA. N = 4 to 6 rats. 
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Discussion  
In this study we have used partially hepatectomized rats to evaluate the effect of hepatic 
regeneration on the in vitro activity of CYP3A using the formation rate of 
6β-hydroxytestosterone. We have also evaluated the effect of cyclosporine and tacrolimus 
on the CYP3A mediated drug metabolism in rats with regenerating livers as these drugs 
are known to be hepatotropic and are expected to increase hepatic regeneration 
(Mazzaferro et al., 1990; Francavilla et al., 1991). 
 
Our results indicate that liver mass recovered gradually to about 72% of the original liver 
mass over a two week period. This value stayed the same on day 18. This agrees with the 
reported 78% liver mass recovery in rats by day 15 after PHx (Maza et al., 2001). This is 
also consistent with a recent observation of recovery of up to 78.6% of ideal liver volume 
in the donors in a living donor liver transplant program (Humur et al, 2004). Liver mass 
recovery in rats was not augmented by chronic treatment with cyclosporine A or 
tacrolimus, which is consistent with data published by Coughlin et al (Coughlin et al., 
1987). 
 
The activity of CYP3A as measured by 6 β-(OH) testosterone and the expression of 
CYP3A protein and mRNA were all reduced in the regenerating liver at 24 hours and on 
day 6, but recovered to normal by day 14.This indicates a definite time dependent change 
in CYP3A activity during hepatic regeneration. Our findings are consistent with some 
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previous studies indicating suppression of CYP3A during the initial part of liver 
regeneration (Starkel et al., 2000; Tamasi et al., 2001; Favre et al., 1998; Ishizuka et al., 
1997). However, most of these studies reported a much earlier recovery of CYP3A 
activity using single point measurements. Our observation indicates that the activity and 
expression of CYP3A to be suppressed much longer and possibly until the liver 
regeneration is complete (14 days). The exact mechanism responsible for the lower 
CYP3A expression and activity during regeneration is currently not known and future 
studies are needed to address this. Interleukin-6 released during hepatic regeneration may 
contribute to the observed decrease in CYP3A expression and activity. It is also likely 
that newly divided cells may have a much lower enzyme expression and activity 
compared to existing liver cells. 
 
Cyclosporine A and tacrolimus can augment DNA synthesis and enhance regeneration by 
non-immunological pathways (Francavilla et al., 1990). So we expected hepatotropic 
effect of cyclosporine A and tacrolimus to be reflected on the recovery of CYP3A 
activity. On the other hand, in vitro incubation with T cells showed that both cyclosporine 
A (100 nM) and tacrolimus (10 nM) suppressed the expression of IL-2, IL-3, IL-4, c-myc, 
and TNF α (Tocci et al., 1989). We also anticipated that the treatment with cyclosporine A 
and tacrolimus would prevent the reduction in the activity of CYP3A due to their effect 
on proinflammatory cytokines. However, in the present study, neither cyclosporine nor 
tacrolimus, at the doses used, altered the activity of CYP3A in rats with regenerating 
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livers. This indicates that any hepatotropic effect of cyclosporine and tacrolimus was not 
reflected in terms of the activity of CYP3A. Moreover, since only serum levels of IL-6 
and three soluble cytokine receptors (TNF α receptor I and II, IL-6 receptor) were 
significantly increased during hepatic regeneration (Fulop et al., 2001), the suppression of 
cyclosporine A and tacrolimus on TNF α and other ILs may have no obvious effect on the 
expression or activity of drug metabolizing enzymes. Direct inhibition of CYP3A by 
cyclosporine A as published previously was observed only at doses much higher than 
what was used in the current study (Brunner et al., 1998). 
 
To the best of our knowledge this is the first study to analyze the recovery profile of 
CYP3A enzyme over time after initiation of regeneration at the level of mRNA 
expression, protein expression and in vitro activity in an animal model. Our study points 
to several important conclusions. CYP3A expression and activity are significantly 
reduced after PHx but recovers completely with time. Second, in spite of an incomplete 
recovery in liver mass on day 14, the functional capacity of the liver (in vitro activity) 
returns to normal. Finally, chronic treatment with cyclosporine A or tacrolimus has no 
effect on CYP3A activity in the regenerating rat livers. The clinical implications of our 
study are 1) the clearance of CYP3A substrates will be transiently decreased in the LDLT 
patients, but will completely recover to normal with time; 2) reduction in doses of drugs 
that are metabolized by CYP3A is needed during the first few weeks after transplantation; 
3) hepatic functional capacity will recover much earlier than the recovery of liver mass; 
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and 4) hepatic regeneration, as determined by the activity of CYP3A, will proceed 
normally in presence of immunosuppressive drug therapy with cyclosporine A and 
tacrolimus. 
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Chapter 3 In Vitro Hepatic Intrinsic Clearance and Pharmacokinetics of Tacrolimus 
Are Transiently Altered during Hepatic Regeneration in Rats 
 
(Part of this chapter is the reprint with permission of the American Society for 
Pharmacology and Experimental Therapeutics. All rights reserved. Tian et al., 2005) 
 
Abstract 
Objective The objective of this study was to evaluate the pharmacokinetics of tacrolimus 
in rats at various time points after initiation of hepatic regeneration by partial 
hepatectomy (PHx).  
Methods The in vitro hepatic clearance of tacrolimus was measured with liver 
microsomes incubated with different concentrations of tacrolimus. The pharmacokinetics 
of tacrolimus was evaluated after intravenous administration of 0.6 mg/kg tacrolimus to 
partially hepatectomized rats. Two hundred microlitter of whole blood was collected at 0, 
0.5, 1, 2, 4, 6, 8, 12 and 24 hours through a jugular vein catheter. The blood concentration 
of tacrolimus was analyzed by a microparticulate enzyme immunoassay (MEIA).  
Results The hepatic intrinsic clearance of tacrolimus was decreased to 72% and 51% of 
that in the control rats at the 24th hour and the 6th day, respectively, but recovered to 
normal level by day 14. A two-compartment model (WinNonlin) fitted the data 
adequately. The total body clearance of tacrolimus was reduced transiently but recovered 
completely by day 18 (4.40 ± 0.50 ml/min/kg (24 hours); 8.64 ± 0.55 ml/min/kg (day 18) 
and 9.22 ± 0.71 ml/min/kg (control)). Other pharmacokinetic parameters such as the area 
under the blood concentration vs time curve (AUC), the terminal disposition rate constant 
Copyright 2004 by the American Society for Pharmacology and Experimental Therapeutics 
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(β) and the terminal disposition half life (T1/2(β)) were also significantly different 
between control and PHx rats. The volume of distribution and other rate constants such as 
K12 and K21 were not altered at any time point after PHx.  
Conclusions 1) During hepatic regeneration, the pharmacokinetics of tacrolimus was 
altered transiently. 2) The magnitude of reduction in in vivo clearance of tacrolimus was 
much less than what was predicted from the loss of liver mass and loss of enzyme activity 
as measured by in vitro studies. 3) The hepatic clearance of other CYP3A substrates will 
also be reduced transiently during the early hepatic regeneration process. 4) The 
magnitude of reduction in in vivo clearance of other CYP3A substrates will be much less 
than what was predicted than the loss of liver mass and loss of enzyme activity as 
measured by in vitro studies. 5) A reduction in the dose of CYP3A substrates that is less 
than the loss of liver mass is sufficient to achieve comparable blood levels of drugs in 
LDLT patients and cadaveric liver transplant patients. 6) The ability of the liver to clear 
drugs recovers completely with time and normal hepatic function will be restored in 
subjects undergoing hepatic resection. 
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Introduction 
Cytochrome P450 3A enzymes account for more than 50% of the drugs metabolized 
through phase I pathways and is also involved in the metabolism of several 
immunosuppressive drugs such as cyclosporine A, tacrolimus and sirolimus. Even though 
the rate of hepatic regeneration may be different between the donor and the recipient in a 
LDLT program, with the donor requiring more regeneration (60% liver regeneration for 
the donor and 40% liver regeneration for the recipient), both the donor and the recipient 
require hepatic regeneration to restore the normal size of the liver. Recently, LDLT 
patients have been reported to achieve higher blood levels of tacrolimus and cyclosporine 
A for a given dose compared to cadaveric liver recipients (Trotter et al., 2002; Taber et 
al., 2002; Morgan et al., 2001). Previous studies (chapter 2) in rats have shown 
suppression of CYP3A during the initial phase of liver regeneration and complete 
recovery of the activity and expression of CYP3A within 2 weeks after initiation of 
hepatic regeneration. The impaired activity of CYP3A in the remaining liver along with a 
reduced liver mass will contribute to the reduced clearance and increased blood levels of 
drugs such as cyclosporine A and tacrolimus. 
 
So it is important to understand whether the magnitude of change in the pharmacokinetics 
of immunosuppressive drugs metabolized by CYP3A during the hepatic regeneration 
process matches the predicted magnitude of change due to a decrease in liver mass and a 
decrease in the intrinsic activity of CYP3A. Nothing is currently known about the 
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pharmacokinetics of immunosuppressive drugs that are metabolized by CYP3A pathway,  
during hepatic regeneration. Such knowledge will help in optimizing not only the 
immunosuppressive drug therapy but also therapy with other drugs that are metabolized 
by CYP3A during hepatic regeneration. In this study, we hypothesized that the clearance 
and in vitro metabolism of tacrolimus will be decreased during hepatic regeneration due 
to the decrease in liver mass and a reduction in the activity of CYP3A in the remaining 
liver lobe. 
 
Materials and Methods 
Chemicals 
Tacrolimus, (10 mg/ml tacrolimus injection - Lot No. 711337K) and 13-demethylated 
tacrolimus were generous gifts from Fujisawa Pharmaceutical Company (Osaka, Japan). 
Heparin injection (Lot No. 322024) was obtained from American Pharmaceutical Partners, 
Inc. (Los Angeles, CA). IMx system and related reagents for measurement of tacrolimus 
blood concentration were obtained from Abbott Laboratories (Abbott Park, IL). All other 
chemicals were purchased from Sigma Chemical Co. (St. Louis, MO). 
 
Animals 
The study protocol was approved by the IACUC at the University of Pittsburgh. Partial 
hepatectomy was performed according to the method of Higgins and Anderson in male 
Sprague-Dawley rats weighing 225-250 g (Higgins and Anderson, 1931) as described in 
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Chapter 2 (For sham operation, please refer to Animals under Methods and Materials 
section in Chapter 2). Medial and left lateral lobes surgically removed during the partial 
hepatectomy procedure served as the control in this study. 
 
Microsome Preparation  
Liver microsomes were prepared by a differential centrifugation procedure as described 
under Methods and Materials section in Chapter 2. 
 
Microsome Incubation with Tacrolimus 
The formation of 13-demethlated tacrolimus (M1) from tacrolimus was also used as a 
marker of CYP3A activity. The incubation was carried out using methods described in 
Microsome Incubation with Testosterone under Methods and Materials section in 
Chapter 2 with different concentration of tacrolimus (0-25 µM) and a fixed concentration 
of the microsomal protein (2.4 mg/ml) (linear to 2.4 mg/ml, Figure 13) for 20 minutes 
(linear to 20 min, Figure 14). The final solution was analyzed for concentration of M1 
using HPLC. 
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 Figure 13. Relationship between microsomal protein concentration and the amount 
of 13-demethylated tacrolimus formed in rat liver microsomes. Concentration of 
tacrolimus: 25 µM; incubation time: 20 min. 
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 Figure 14. Relationship between time of incubation and the amount of 
13-demethylated tacrolimus formed in rat liver microsomes. Concentration of 
tacrolimus: 25 µM; microsomal protein concentration: 1.8 mg/ml;  
 
Pharmacokinetic Study of Tacrolimus 
Pharmacokinetic studies were carried out in rats in the control group, 24 hours after PHx, 
14 days after PHx and 18 days after PHx. Since there was no significant difference 
between control group and sham group in the in vitro intrinsic clearance of tacrolimus at 
any time, pharmacokinetic studies were not conducted in sham group (Table 2). A silastic 
tubing was inserted into the jugular vein 24 hours before the study. Rats were anesthetized 
with methoxyflurane inhalation (in control rats not undergoing PHx) or continued 
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methoxyflurane anesthesia in the rats undergoing surgery. Rats were restrained in the 
triangular shaped plastic bag with an opening at the tip for the rat to inhale the anesthetic. 
The extended toe pinch reflex was used to determine the depth of anesthesia. When 
anesthesia was appropriate, rats were turned on their back and an incision was made at 
the location of the jugular vein around the neck using sterile techniques with sanitized 
instruments. The jugular vein was revealed, the blood supply was stopped, and a small 
hole was made in the vein using fine tipped instruments. A PE-60 catheter tubing 
connected to a syringe filled with 100U/mL heparinated saline was inserted. A small plug 
was used to seal off the tubing. The tubing was secured with suture. A small incision was 
made at the top of the rat’s back and the tubing was pulled through so the rat didn’t 
damage the tubing.  
 
On the study day, tacrolimus(0.6 mg/kg) was administered intravenously through the 
jugular vein catheter. A sterile syringe (1 cc) was used for the collection of each blood 
sample. First, fluid in the catheter and 0.1 ml blood was taken out by a 1cc syringe 
containing 0.2 ml 100 u/ml heparinized saline solution; then 0.2 ml blood sample was 
withdrawn for tacrolimus analysis; and finally the initial fluid plus blood together with 
0.2 ml 100 u/ml heparin saline was injected back. Multiple blood samples were collected 
in heparinized tubes at 0, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours after intravenous 
administration of tacrolimus.  
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HPLC Analysis of 13-demethylated Tacrolimus 
As per the method described previously (Perotti et al., 1994b) with minor modifications, 
one hundred µl of the incubation solution was injected onto a LiChrospher RP-18 column 
(250 mm x 4.6 mm, 5 µ) heated to 60ºC. The UV detector was set at 214 nm. The mobile 
phase consisted of a mixture of acetonitrile/method/diluted O-phosphoric acid, pH 3.0, 
49/3/48. The initial flow rate was 1 ml/min for the first 20 minutes, stepped up to 1.5 
ml/min within 0.5 min and maintained for the subsequent 23 minutes. The retention time 
for M1 was 9.3 minutes and the total run time was 43 minutes. The standard curve was 
linear over a range of 0.25-5 µg. The intra- and inter-day CV(%) at 0.5 µg and 5 µg was 
less than 7% (n = 5). 
 
Microparticulate Enzyme Immunoassay of Tacrolimus Blood Concentration 
Tacrolimus concentration in the blood was measured by a microparticulate enzyme 
immunoassay (MEIA) using Abbott’s IMx analyzer. Each blood sample, calibrator or 
control was individually mixed thoroughly. One hundred fifty µl of each sample (diluted 
to the linear range with blank blood when necessary), the calibrator or control was 
pipetted into a fresh 1.5 ml tube and 150 µl of IMx Tacrolimus II Whole Blood 
Precipitation Reagent was added. Each tube was vortexed and centrifuged at 13,000 rpm 
for 4 min. The tubes were uncapped and the supernatant was decanted into the sample 
well of an IMx reaction cell. The measurement was done automatically using IMx 
Tacrolimus II Reagent Pack containing mouse monoclonal anti-tacrolimus antibody 
 63
coated microparticles and tacrolimus alkaline phosphatase conjugate in a IMx system. 
The antibody used in the assay does not cross-react with the major metabolite, 
(representing more than 75% of total metabolites formed) M1. Cross reactivity has been 
observed only with a few minor metabolites. Based on this, the antibody used primarily 
measures only tacrolimus. The calibration curve, ranging from 2 ng/ml to 30 ng/ml, was 
generated using reagents supplied in the kit. The intra-day and inter-day CV (%) at 3 
ng/ml, 12 ng/ml and 25 ng/ml was less than 14% (n =5). With each run of the samples, 
three controls with concentrations of 5 ng/ml, 11 ng/ml and 22 ng/ml were also run. 
 
Data Analysis 
Enzyme kinetic analysis was performed using Prism 3.0 (GraphPad Software Inc., San 
Diego, CA). The kinetic parameters (Km and Vmax) for the formation of 13-demethylated 
tacrolimus were calculated using nonlinear regression analysis. The intrinsic clearance 
(Clint) was calculated as Vmax/Km. Pharmacokinetics of tacrolimus was analyzed by fitting 
a biexponential equation to the data using WinNonlin 3.1 (Pharsight Co., Mountain View, 
CA). The selection of the kinetic model was made using AKAIKE information criterion 
(AIC) and the precision of the estimated parameters. All data are reported by mean ± SD. 
Comparisons among groups were made via a one way analysis of variance with Tukey 
post hoc analysis (P < 0.05). For sample size calculation, based on the initial 
measurement of AUC in control group, 1089 ± 83.05 hr*ng/ml, to observe a 20% 
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difference between groups, with a power of 80% and α = 0.05, the sample size required was 
3 rats. Experiments were completed with 4 to 6 rats in each group. 
 
Results 
Measurement of Vmax, Km, and CLint for the Formation of 13-demethylated Metabolite of 
Tacrolimus  in Hepatic Microsomes 
Both Vmax and Km values were not different between control group and sham group at 
all time points studied (Table 2). The Vmax for the formation of M1 in hepatic 
microsomal fraction obtained at the 24th hour after PHx was significantly decreased 
compared to control value (Table 2). On day 6, the Vmax still remained at a lower level 
(50% of control level) but recovered completely by day 14 during hepatic regeneration 
(90% of control level). However, the Km values were similar among all the groups. The 
intrinsic clearance (CLint) for the formation of M1 in the hepatic microsomal fraction was 
significantly decreased during hepatic regeneration at the 24th hour and on day 6. 
 
Pharmacokinetics of Tacrolimus  
The blood concentration vs. time curve of tacrolimus after intravenous administration of 
tacrolimus was well described by a biexponential process (Figure 15). The 
pharmacokinetic parameters of tacrolimus at different time points after initiation of the 
regeneration are summarized in Table 3. The area under the blood concentration vs time 
curve (AUC), the total body clearance (CL), the terminal disposition rate constant (β) and 
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the terminal disposition half life (T1/2(β)) were significantly different between control 
and PHx rats. The total body clearance of tacrolimus at the 24th hour was much lower than 
that in the control group. The clearance of tacrolimus increased significantly on day 14 
from values observed at the 24th hour but was still lower than the clearance in the control 
group. There was no significant difference in total body clearance on day 18 and control 
group. The volume of distribution and other rate constants such as K12 and K21 were not 
altered at any time point. 
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Table 2. Mean ( ± SD) Vmax, Km and CLint for the formation of 13-demethyled 
metabolite (M1) of tacrolimus in hepatic microsomes (N = 4-6 rats). 
Time after 
PHx 
Groups Vm (nmol/mg 
protein/min) 
Km (µM) CLint (ml/min/mg 
protein)  
Control 0.40 ± 0.06  4.87 ± 0.69  0.082 ± 0.007 
Sham 0.41 ± 0.03  5.28 ± 0.55  0.079 ± 0.011 
 
24-hour 
PHx 0.30 ± 0.03b  5.10 ± 0.85 0.059 ± 0.005a
Control 0.36 ± 0.07  5.29 ± 0.80  0.068 ± 0.008 
Sham 0.38 ± 0.05  5.16 ± 0.73 0.075 ± 0.018 
 
6-day 
PHx 0.18 ± 0.02a 5.18 ± 0.74 0.035 ± 0.003a
Control 0.42 ± 0.03 5.04 ± 0.88 0.085 ± 0.018 
Sham 0.40 ± 0.03 5.00 ± 0.68 0.081 ± 0.013 
 
14-day 
PHx 0.38 ± 0.04 4.90 ± 0.75 0.079 ± 0.011 
a P < .01; b P < .05 (vs. control, Tukey post hoc analysis). 
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 Figure 15. Blood concentrations of tacrolimus vs time profile at different time points 
after initiation of hepatic regeneration. Data was represented by mean + SD (N = 4 to 
6 rats). 
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Table 3. Pharmacokinetic parameters of tacrolimus (0.6 mg/kg, i.v.) 24 hours, 14 
days and 18 days after partial hepatectomy (N = 4 to 6 rats) 
Parameters Control PHx (24-hour) PHx (14-day) PHx (18-day) 
AUC 
(hr•ng/ml)** 
1089.29 ± 83.05 
 
2297.60 ± 260.51a 1575.97 ± 144.99a 1160.75 ± 74.62 
CL 
(ml/min/kg)** 
9.22 ± 0.72 4.40 ± 0.50a 6.39 ± 0.61a 8.64 ± 0.55 
β ((hr-1)* 0.31 ± 0.12 0.10 ± 0.05b 0.24 ± 0.04 0.24 ± 0.10 
t1/2,β (hr)* 2.53 ± 0.97 8.67 ± 4.48b 2.98 ± 0.52 3.14 ± 1.10  
K10 (hr-1)** 2.31 ± 0.74 0.83 ± 0.25b 2.88 ± 0.51 2.67 ± 0.28 
K12 (hr-1) 1.12 ± 0.40 1.25 ± 0.17 1.03 ± 0.50 1.43 ± 0.54 
K21 (hr-1) 0.40 ± 0.25 0.49 ± 0.20 0.35 ± 0.04 0.29 ± 0.07 
Vss (ml/kg) 718.53 ± 258.20 895.74 ± 272.98 653.37 ± 192.74 658.31 ± 274.50 
** P < .01, * P < .05 for ANOVA; a P < .01, b P < .05 (vs. control) was obtained from 
Tukey post hoc analysis. 
Abbreviations: AUC, area under the blood concentration vs time curve; CL, total body 
clearance; t1/2, β = disposition half life; Vss = volume of distribution at steady state. 
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Discussion 
In this study we have used partially hepatectomized rats to evaluate the effect of hepatic 
regeneration on the pharmacokinetics of tacrolimus. This study simulates what is likely to 
happen to the drug metabolizing capacity in the donor in a living donor liver transplant 
program. In addition to hepatic regeneration, additional factors such as cold ischemia, 
warm reperfusion injury and immunosuppressive drug therapy can also modify drug 
metabolizing capacity in the recipient. In this study, tacrolimus was used as a 
representative marker drug for CYP3A.  
 
Tacrolimus is primarily eliminated by hepatic metabolism (hepatic clearance is close to 
total body clearance as only 0.5% unchanged tacrolimus was recovered in human after IV 
dosing of tacrolimus (Moller et al., 1999)) through the formation of M1 (representing 
75% of the total metabolites, Perotti et al., 1994) and the CYP3A enzyme appears to be 
responsible for the formation of M1 (Shiraga T et al., 1994). Alterations in the hepatic 
function due to drug or disease state have been associated with altered ability of the liver 
to clear tacrolimus (Venkataramanan et al., 1995). In our studies, the magnitude in 
reduction in the liver mass at 24 hrs was 69%. The ability of CYP3A in the liver to 
metabolize testosterone in vitro (chapter 2) and to metabolize tacrolimus was also 
reduced in the regenerating liver at 24 hours and on day 6. Taking into consideration the 
reduction in liver mass and the decrease in the hepatic intrinsic clearance of tracrolimus 
normalized to protein amount (assuming that hepatic M1 formation clearance 
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approximates the hepatic intrinsic clearance of tacrolimus, because majority of tacrolimus 
is metabolized to M1 and that all other pathways of tacrolimus metabolism will behave 
similar to M1 pathways, as these metabolites are also formed by CYP3A), the whole liver 
intrinsic clearance for tacrolimus must decrease to 21% of normal liver at the 24th hour 
after initiation of hepatic regeneration (71% of control intrinsic clearance times 31% of 
normal liver mass 24 hours after PHx). Based on the total body clearance of tacrolimus in 
control rats (9.22 ml/min/kg) and the reported blood flow of 55.2 ml/min/kg (Davies and 
Morris, 1993), assuming lack of any change in the unbound fraction of tacrolimus as red 
blood cells are primarily responsible for binding tacrolimus in blood (Venkataramanan et 
al., 1995) and hematocrit did not change during hepatic regeneration (Okano et al., 2001; 
Kurata et al., 2000; Eguchi et al., 1998), the following relationship can be established for 
tacrolimus at 24 hrs: 
 
CL = Q*fu*Clint/(Q+fu*Clint)                                     (1) 
CL: hepatic clearance or total body clearance for tacrolimus 
Q: hepatic blood flow 
fu: unbound fraction of tacrolimus 
Clint: hepatic intrinsic clearance for tacrolimus 
 
CL = 9.22 ml/min/kg (data from control group)                         (2) 
Q = 55.2 ml/min/kg (data from Davies and Morris, 1993)                 (3) 
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fu*Clint = 11.07 ml/min/kg (from equation 1, 2, and 3)                   (4) 
 
At the 24th hour after PHx, we have: 
CLPHx,predicted = Q*fu*0.21Clint/(Q+ fu*0.21Clint)                       (5)  
(Hepatic intrinsic clearance at the 24th hour after PHx was only 21% of that observed in 
the control group.) (remaining hepatic clearance (%) when normalized to per unit liver 
mass: 71% (Table 2); remaining liver mass (%): 31% (Figure 7)) 
CLPHx,predicted: predicted total body clearance 24 hours after PHx = 2.22 ml/min/kg 
 
At the 14th day after PHx, we have: 
CLPHx, predicted = Q* fu*0.67Clint/(Q+ fu*0.67Clint) 
(Hepatic intrinsic clearance at the 14th day after PHx was about 67.24% of that observed 
in the control group.) (remaining hepatic clearance (%) when normalized to per unit liver 
mass: 92% (Table 3); remaining liver mass (%): 72% (Figure 7)) 
CLPHx,predicted: predicted total body clearance 14 days after PHx = 6.54 ml/min/kg                       
   
However, while the total body clearance of tacrolimus was significantly decreased (4.4 
ml/min/kg) twenty four hours after PHx, the magnitude was much less than what was 
predicted based on in vitro data. Taking account of the low activity (undectable activity in 
microsomes) and small organ mass, the contribution of small intestine and kidney to the 
metabolism of tacrolimus is expected to be negligible in rats after intravenous 
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administration. When normalized to the predicted liver weight at the 24th hours, the 
clearance per unit liver weight calculated as shown below was increased significantly 
during hepatic regeneration (24-PHx vs. control: 0.33 ml/min/g vs. 0.23 ml/min/g). 
 
Given the observed clearance in the control rats of 9.22 ml/min/kg, for a rat with 250 g 
body weight and an average liver weight of 10 g (N= 6 rats), the clearance will be 0.23 
ml/min/g liver (CL = (9.22 ml/min/kg*0.25 kg)/10 g liver). 
 
Given the observed clearance in the rats with a regenerating liver (24 hr) of 4.40 
ml/min/kg, for a rat with 250 g body weight and an average liver weight of 3.3 g (N = 6 
rats), the clearance will be 0.33 ml/min/g liver (CLPHx = (4.40 ml/min/kg*0.25 kg)/3.3 g 
liver) at the 24th hour after PHx.  
 
These observations point to a significant reserve capacity of the liver to clear drugs from 
the body during the regeneration process. Since tacrolimus is a low hepatic extraction 
ratio drug (0.167, total body clearance 9.22 ml/min/kg divided by reported blood flow 
55.2 ml/min/kg (Davies and Morris, 1993)), increased blood flow per unit weight of the 
liver per se had little effect on the clearance of tacrolimus. It is interesting to note that 
while higher blood level of tacrolimus normalized to unit dose have been reported in 
LDLT recipients compared to those receiving cadaveric livers, this increase was also 
much smaller (26%) (Trotter et al., 2002) than what is expected based on the smaller liver 
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volume and the expected impairment in the metabolic activity of the liver. It is possible 
that increased blood flow per unit weight of the liver due to PHx increases percentage of 
hepatocytes involving in the drug metabolism (Under normal situation, a lower 
percentage of hepatocytes will be involved in the drug metabolism). The precise 
mechanism for this needs to be evaluated in future studies. Additionally, when comparing 
the values of K10, K12 and K21, the K21 has the smallest value which implies that the back 
distribution of tacrolimus from compartment 2 to compartment 1 is the rate limitation 
step of the elimination. This may also be the reason for the reserve capacity of the liver in 
the metabolism of tacrolimus. 
 
To the best of our knowledge this is the first study to evaluate the pharmacokinetics of 
tacrolimus and to analyze the recovery profile of the pharmacokinetics of tacrolimus over 
time after initiation of hepatic regeneration in an animal model. Our study provides 
several implications for use of drugs metabolized by CYP3A in LDLT patients: 1) The 
hepatic clearance of CYP3A substrates will also be reduced transiently during the early 
hepatic regeneration process. 2) The magnitude of reduction in in vivo clearance of CYP3A 
substrates will be much less than what was predicted than the loss of liver mass and loss of 
enzyme activity as measured by in vitro studies. 3) A reduction in the dose of CYP3A 
substrates that is less than the loss of liver mass is sufficient to achieve comparable blood 
levels of drugs in LDLT patients and cadeveric liver transplant patients. 4) Caution must 
be exercised in using in vitro data to predict in vivo clearance of drugs by the 
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regenerating liver. 5) Living donor liver transplant patients would require a dose of 
CYP3A substrates that is not proportion to the loss of the liver mass. Finally, drug dosing 
in LDLT patients must be routinely monitored. 6) The ability of the liver to clear the drug 
the drug recovers completely with time and normal hepatic function will be restored in 
subjects undergoing hepatic resection. 
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Chapter 4 Activity and Expression of Various Isoforms of Uridine Diphosphate 
Glucuronosyltransferase (UGT) Are Differentially Regulated during Hepatic 
Regeneration in Rats 
 
Abstract 
Objective The objective of this study was to evaluate the activity and expression of 
various UGTs in rats at various time points after initiation of hepatic regeneration by 
partial hepatectomy (PHx). 
Methods The mRNA expression of various UGTs was assessed using real-time PCR with 
specific primers. The in vitro activity of several UGTs was measured with liver 
microsomes incubated with different substrates such as estradiol (UGT1A1), 
acetaminophen (UGT1A6/7), morphine (UGT2B1), testosterone (UGT2B1/3/6), 
androsterone (UGT2B2), and (-)- borneol (UGT2B12).  
Results While the activity of UGT1A1, UGT2B1, UGT2B2, UGT2B1/3/6 and UGT2B12 
was decreased, the activity of UGT1A6/7 was preserved during hepatic regeneration. All 
UGTs with the altered activity or expression recovered differentially, with some returning 
to normal levels by day 6 (UGT1A3, UGT2B1, UGT2B2, and UGT2B12) and others 
recovering by day 14 (UGT1A1, UGT2B1/3/6 and UGT2B8) after initiation of hepatic 
regeneration.  
Conclusion During hepatic regeneration, the hepatic UGT activity and the mRNA 
expression of several UGTs were decreased and different isoforms recovered 
differentially over time. The clearance of most of the substrates of UGT will be decreased 
significantly in LDLT patients due to the loss of liver mass and decreased activity of the 
 76
remaining liver mass. The activity of UGTs will normalize with time as the hepatic 
regeneration progresses. Individualized dosing regimen for different UGT substrates may 
be needed when using UGT substrates in LDLT patients. 
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Introduction 
Living donor liver transplant patients are normally treated with drugs such as tacrolimus, 
sirolimus and cyclosporine, which are metabolized by phase 1 pathways and mycophenolic 
acid, acetaminophen, and morphine, which are metabolized through phase 2 pathways 
(glucuronidation). In addition, several endogenous compounds such as bilirubin, estradiol, 
androsterone, and testosterone are metabolized by glucuronidation. Cytokines that are 
released during the regeneration process are known to regulate uridine diphosphate 
glucuronosyltransferases (UGTs) in the liver (Monshouwer et al., 1996; Strasser et al., 
1998). So we hypothesized that the activity and expression of all UGT isoforms will be 
altered during hepatic regeneration. While the expression and activity of phase 1 enzymes 
have been reported to be decreased during hepatic regeneration, there is controversial and 
incomplete information on the activity and expression of uridine diphosphate 
glucuronosyltransferases (UGTs) during hepatic regeneration. Some publications indicate 
a change, while others indicate a lack of change in UGT expression or activity (Catania et 
al., 1998; Iversen et al., 1985; Pellizzer et al., 1996; Zakko et al., 1996). Moreover, 
previous studies on the expression of UGTs have used northern blot. Compared to the 
conventional northern blot method for the measurement of RNA expression, real-time 
PCR is a more sensitive, quantitative, accurate and reliable assay for measurement of 
mRNA.  
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Systematic study of the activity and expression of UGTs is necessary to thoroughly 
understand the regulation of UGT isoforms during hepatic regeneration. This information 
is important in order to optimize drug therapy and understand the metabolism of various 
drugs and endogenous compounds in LDLT patients. We hypothesized that the expression 
and in vitro activity of various forms of UGT will be decreased during the initial pahse of 
hepatic regeneration due to decreased expression of transcription factors involved in their 
regulation as a result of increased cytokine levels. In this study, we have utilized partially 
hepatectomized rats and real-time PCR to systematically study the effect of hepatic 
regeneration on the activity and expression of different UGTs using specific markers and 
specific primers.  
 
Materials and Methods 
Chemicals 
Estradiol, estradiol-3-glucuronide, acetaminophen, acetaminophen glucuronide, morphine 
sulfate, morphine-3-glucuronide, androsterone, testosterone glucuronide, (-)-borneol, and 
UDPGA were purchased from Sigma Chemical Co. (St. Louis, MO). Testosterone was 
obtained from Steraloids Inc. (Newport, RI). UDP-[U-14C]glucuronic acid was bought 
from MP Biomedicals (Irvine, CA). Reagents for reverse transcription were purchased 
from Promega (Madison, WI). Forward and reverse primers for UGTs, constitutive 
androstane receptor (CAR), pregnane X receptor (PXR), hepatocyte nuclear factor 1 
(HNF1) and beta-2-microglobulin (beta-2-m) were synthesized by Applied Biosystems 
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(Forest city, CA). Forward and reverse primers for C/EBP α were synthesized by 
Integrated DNA Technologies, Inc. (Coralville, IA). All solvents were HPLC grade. 
 
Animals 
Partial hepatectomy was performed and livers were collected using the methods described 
in Chapter 2. 
 
Preparation of Microsomes 
Liver microsomes were prepared by differential centrifugation procedures described in 
Chapter 2.  
 
Incubation of UGT substrates in Microsomes 
The microsomes were incubated with various substrates to measure the in vitro activity 
(estradiol as a UGT1A1 marker; acetaminophen as a UGT1A6/7 marker; morphine as a 
UGT2B1 marker; testosterone as a UGT2B1/3/6 marker; androsterone as a UGT2B2 
marker; (-)- borneol as a UGT2B12 marker (Senafi et al., 1994; King et al., 1996; Kessler 
et al., 2002; Mackenzie et al., 1996; Burchell, 1999). Incubation conditions were the same 
as those reported in the literature: estradiol (150 µM), acetaminophen (10 mM); morphine 
(10 mM); and testosterone (150 µM) (Alkharfy and Frye, 2002; Fisher et al., 2000; 
Narayanan et al., 2000).  
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For androsterone (200 µM) (reported Km: 7.2 µM, Rittmaster et al., 1989) and (-)- 
borneol (500 µM) (reported Km: 36 µM, Green et al., 1995), the incubation procedure 
was established as follows: A solution (250 µl) containing 1 mg/ml microsomal protein, 2 
mM UDPGA (including 0.2 µCi UDP-[U-14C]glucuronic acid/reaction for androsterone 
or 0.1 µCi UDP-[U-14C]glucuronic acid/reaction for (-)- borneol), 10 mM MgCl2, Brij 58 
(0.1 mg/mg protein) and 200 µM androsterone or 500µM (-)- borneol was incubated for 
60 min at 37°C in a shaking water bath. Then 25 µl of 6% perchloric acid was added to 
the incubation solution. After centrifugation at 13,000 rpm for 5 minutes, 100 µl of the 
supernatant was analyzed by high performance liquid chromatographic (HPLC) methods. 
 
Assays 
The concentration of the glucuronide metabolites in the supernatant was measured based 
on published HPLC methods, with minor modifications as shown in Table 4. The 
correlation coefficients (r2) for the standard curves were ≥ 0.98, and the coefficient of 
variation was less than 3% for all the analytical methods used (n = 3). The peaks for both 
androsterone glucuronide and borneol glucuronide were identified by comparing samples 
incubated with or without radiolabeled UDPGA. No standard curves were established for 
the measurement of the radioactivity of the glucuronide of androsterone and borneol; 
however, the radioactivity was measured within the linear range of the detector. 
 
 
 81
Table 4. Methods for measuring the in vitro activity of UGTs  
UGT 
isoform 
S: Substrate 
M: Metabolite  
HPLC Method Reference 
1A1 S: estradiol 
M: 
estradiol-3-glucuronide 
Column: Alltima C18 (250 mm X 4.6 mm, 5 µ 
Mobile phase: acetonitrile/50 mM ammonium 
phosphate buffer (pH 3) (35/65, v/v), 1 ml/min 
Fluorescence detector: excitation (210 nm), emission 
(300 nm). 
Retention time: 4.5 min. 
Linear range: 30-750 pmol 
CV(%) (n = 3): less than 3% 
Alkharfy and 
Frye, 2002 
(with minor 
modification) 
1A6/7 S: acetaminophen 
M: acetaminophen 
glucuronide 
Column: LiChrospher RP-18 (250 mm X 4.6 mm, 5 µ 
Mobile phase: acetonitrile/10 mM phosphoric acid 
(pH 2.3) (3.75/96.25, v/v), 1.7 ml/min 
UV detector: 254 nm 
Retention time: 7.1 min 
Linear range: 0.4-8 nmol 
CV(%) (n = 3): less than 3% 
Kessler et al., 
2002 (with 
minor 
modification) 
2B1 S: morphine 
M: 
morphine-3-glucuronide 
Column: Alltima C18 (250 mm X 4.6 mm, 5 µ 
Mobile phase: acetonitrile/50 mM KH2PO4 (10/90, 
v/v), 1 ml/min 
Fluorescence detector: excitation (210 nm), emission 
(350 nm). 
Retention time: 3.7 min 
Linear range: 0.15-8 nmol 
CV(%) (n = 3): less than 3% 
Fisher et al., 
2000 (with 
minor 
modification) 
2B2 S: androsterone Column: LiChrospher RP-18 (250 mm X 4.6 mm, 5 µ Rittmaster et 
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M: androsterone 
glucuronide 
Mobile phase: acetonitrile/0.1% trichloroacetic acid 
(40/60, v/v), 1 ml/min; scintillation cocktail: 3ml/min 
Radioactivity detector (Packard 500TR): 14C 
Retention time: 11.8 min 
al., 1989 
(with minor 
modification) 
2B1/3/6 S: testosterone 
M: testosterone 
glucuronide 
Column: Alltima C18 (250 mm X 4.6 mm, 5 µ 
Mobile phase: phase A, acetonitrile/50 mM 
ammonium phosphate (pH 4.5) (30/70, v/v); phase B, 
methanol. (0-7.5 min, 1 ml/min of phase A; 7.5-8 
min, gradient from 1 ml/min phase A to 1.2 ml/min of 
phase B; 8-17 min, 1.2 ml/min of phase B; 17-17.2 
min, gradient from 1.2 ml/min of phase B back to 1.2 
ml/min of phase A; 17.2-27 min, 1.2 ml/min of phase 
A.) 
UV detector: 250 nm 
Retention time: 6.3 min 
Linear range: 0.15-4 nmol 
CV(%) (n = 3): less than 3% 
Narayanan et 
al., 2000 
(with minor 
modification) 
2B12 S: (-)-borneol 
M: borneol glucuronide 
Column: LiChrospher RP-18 (250 mm X 4.6 mm, 5 µ 
Mobile phase: acetonitrile/0.1% trichloroacetic acid 
(40/60, v/v), 1 ml/min; scintillation cocktail: 3ml/min 
Radioactivity detector (Packard 500TR): 14C 
Retention time: 6.6 min 
Same as the 
method for 
androsterone 
glucuronide 
(UGT2B2) 
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Extraction of RNA and Reverse Transcription   
Total RNA extraction and reverse transcription were conducted using the methods 
described in Chapter 2. 
 
Real-Time PCR   
PCR was performed as described in Chapter 2. Forward and reverse primers for UGT1A 
and 2B family, CAR, PXR, HNF-1, C/EBP α and beta-2-microglobulin (beta-2-m), were 
designed using the combination of Blast 2 
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html), Amplify 1.2 (freeware from 
http://engels.genetics.wisc.edu/amplify/) and Primer Express 2.0 (Applied Biosystems), 
and are listed in Table 5.  
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Table 5. Primers for real-time PCR analysis of mRNA expressions  
Gene GenBank No. Primers Base Positions 
 
Amplicon 
Size 
Beta-2-m NM_012512 Forward 5’-cgtgcttgccattcagaaaa-3’ 
Reverse 5’-gaagttgggcttcccattctc-3’ 
58-77 
113-133 
76 
UGT1A1 NM_012683 Forward 5’-gccatgcagcctggattt-3’ 
Reverse 5’-ctcttgggcacgtaggacaac-3’ 
549-567 
592-612 
64 
 
UGT1A2 D38066 Forward 5’-cgcaaattcttgtgcagctcta-3’ 
Reverse 5’-accacatcgaaggaactggaa-3’ 
368-390 
423-443 
76 
 
UGT1A3 D38067 Forward 5’-ggccatgtacctgcgtgttc-3’ 
Reverse 5’-tgcttcaaattccagttcacaga-3’ 
473-493 
521-543 
71 
 
UGT1A5 AF461734 Forward 5’-tcgacagttctcttaaggtcttgtatg-3’ 
Reverse 5’-aaggagctggaattcagatgct-3’ 
395-422 
451-472 
78 
 
UGT1A6 NM_057105 Forward 5’-ccgctatcgctcctttgg-3’ 
Reverse 5’-ctgtactctcttagaggagccatcag-3’ 
356-374 
403-428 
73 
 
UGT1A7 NM_130407 Forward 5’-cagaccccggtgactatgaca-3’ 
Reverse 5’-caacgtgaagtctgtgcgtaaca-3’ 
750-771 
800-822 
73 
 
UGT1A8 NM_175846 Forward 5’-gagggcatgaggtggtggta-3’ 
Reverse 5’-cacggtaaaattcagcgactttc-3’ 
154-174 
203-225 
72 
 
UGT2B1 M13506 Forward 5’-ctgaagcagagccctgagaga-3’ 1626-1647 76 
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Reverse 5’-gggaaggcactggcatga-3’ 1684-1701  
UGT2B2 J02589 Forward 5’-ggcagggcagcagtcatc-3’ 
Reverse 5’-cctacttcttgctcactctctgctt-3’ 
2182-2200 
2243-2267 
86 
 
UGT2B3/6 M31109 (2B3) 
 
M33746 (2B6) 
Forward 5’- atgccaagaaatgggatcca-3’ 
Reverse 5’- tgcccattgtctcagctaagg-3’ 
Same primers as the pair for 2B3 
717-736 
768-788 
728-747a
779-799 
72 
 
72 
UGT2B8 U27518 Forward 5’-tgaacaaaatgttcgggcaat-3’ 
Reverse 5’-aagttccttgtttgaaacaacttctct-3’ 
363-384 
411-437 
75 
 
UGT2B12 U06273 Forward 5’-tgctgcaaataagtttctgctttaa-3’ 
Reverse 5’-tgactatattccatcggccatacc-3’ 
33-58 
83-106 
74 
 
CAR NM_022941 Forward 5’-cggagtataaacagcgcatactca-3’ 
Reverse 5’-aagcagcggcatcatagca-3’ 
1190-1213 
1243-1261 
72 
PXR NM_052980 Forward 5’-cggctacctgcggtgttt-3’ 
Reverse 5’-caacagtgaggcctgcagaa-3’ 
725-742 
768-787 
63 
HNF 1 X54423 Forward 5’-ctcctcggtactgcaagaaacc-3’ 
Reverse 5’-ttgtcaccccagcttaagactct-3’ 
3061-3082 
3111-3133 
73 
C/EBP α NM_012524 Forward 5’-tatagacatcagcgcctacatcga-3’ 
Reverse 5’-ccggctgtgctggaagag-3’ 
183-206 
241-258 
76 
aone mismatch at position 738. 
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 The specificity of each pair of primers was first evaluated using nucleotide-nucleotide 
Blast to confirm that there was no match between the primers described in Table 5 and 
the rat genome except for the individual UGTs (primers for UGTs) or for targeting genes 
(primers for CAR, PXR, HNF-1, C/EBP α, beta-2-m). The primer specificity was further 
checked (using Amplify 1.2) for any potential amplification of UGT isoforms other than 
the target isoform. Because of the high homology between UGT2B3 and UGT2B6, the 
primers were designed for both isoforms when using real-time PCR for specific 
measurements. For each pair of primers, the control without reverse transcriptase was 
also used for PCR reactions in duplicate to confirm that there was no genomic DNA 
contamination in the cDNA samples. 
 
Data Analysis 
All data are reported as mean ± SD. Comparisons between groups were made by 
student’s t-test (P < 0.05). For sample size calculation, the initial formation rate of 
estradiol-3-glucuronide from liver lobes of sham (6 days) (258.61 ± 33.28 nmol/mg 
protein/min) was used. With a power of 80% and α = 0.05, to detect a 25% difference, 4 
rats were required. Experiments were completed with 4 to 6 rats in each group. 
 
Results 
Activity and Expression of UGT1A1 during Hepatic Regeneration 
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The activity of UGT1A1 was decreased 24 hours and 6 days after PHx and recovered by 
day fourteen (Figure 16, panel A). The mRNA expression of UGT1A1 was also 
decreased 24 hours after initiation of regeneration and returned to normal level by day 14 
(Figure 16, panel B). 
 
Activity and Expression of UGT1A6/7 during Hepatic Regeneration 
The activity of UGT1A6/7 was preserved at all time points studied (Figure 17, panel A). 
The mRNA expressions of both UGT1A6 and UGT1A7 also stayed at the control level as 
measured in the paired sham group during hepatic regeneration (Figure 17, panel B). 
 
Activity and Expression of UGT2B1 during Hepatic Regeneration 
The activity of UGT2B1 was decreased 24 hours after PHx (Figure 18, panel A). The 
mRNA expression of UGT2B1 was also decreased 24 hours after regeneration and 
returned to normal level as measured in the paired sham group by day 6 (Figure 18, panel 
C). 
 
Activity and Expression of UGT2B1/3/6 during Hepatic Regeneration 
The activity of UGT1/3/6 measured using testosterone was decreased 24 hours and 6 days 
after PHx and recovered by day fourteen (Figure 18, panel B). The mRNA expression of 
UGT2B3/6 was also much lower at 24 hours and 6 days (Figure 18, panel D). 
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Activity and Expression of UGT2B2 during Hepatic Regeneration 
Both the activity and mRNA expression of UGT2B2 were decreased after initiation of 
hepatic regeneration and recovered completely by day 6 (Figure 19). 
 
Activity and Expression of UGT2B12 during Hepatic Regeneration 
Both the activity and mRNA expression of UGT2B2 were decreased after initiation of 
hepatic regeneration and recovered completely by day 6 (Figure 20). 
 
Expression of other UGTs (UGT1A2, UGT1A3, UGT1A5, UGT1A8 and UGT2B8) 
during Hepatic Regeneration 
UGT1A2 and UGT1A3 mRNA was up-regulated compared to sham groups during 
hepatic regeneration (Figure 21, panel A and B). The mRNA expressions of UGT1A5, 
and UGT1A8, were not altered at any time during the regeneration process (Figure 21, 
panel C and D). UGT2B8 was down-regulated compared to sham groups (Figure 21, 
panel E).  
 
The mRNA Expression of CAR, PXR, HNF1 and C/EBP α during Hepatic 
Regeneration 
CAR, PXR and HNF1 genes were expressed stably 24 hours after PHx. The C/EBP α 
gene was down-regulated 24 hours after initiating hepatic regeneration (Figure 22) and 
recovered back to normal level by day 6. 
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 Figure 16. The activity and mRNA expression of UGT1A1 at different time points 
after PHx. Sham: liver lobes from sham groups; PHx, the regenerated liver lobes after 
PHx. The activity was measured using liver microsomes prepared as described in the 
Methods section. The relative mRNA level was determined by real time PCR as 
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described in Methods using pooled cDNAs generated from total RNAs from 6 normal 
livers as the standard. The arbitrary mRNA values were normalized with their respective 
beta-2-m values. All data are expressed as mean ± SD. ** P < .01 vs. sham; * P < .05 vs. 
sham (student’s t-test). N = 4 to 6. 
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 Figure 17. The activity and mRNA expression of UGT1A6/7 at different time points 
after PHx. Sham: liver lobes from sham groups; PHx, the regenerated liver lobes after 
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PHx. The activity was measured using liver microsomes prepared as described in the 
Methods section. The relative mRNA level was determined by real time PCR as 
described in Methods using pooled cDNAs generated from total RNAs from 6 normal 
livers as the standard. The arbitrary mRNA values were normalized with their respective 
beta-2-m values. All data are expressed as mean ± SD. P > .05 vs. sham (student’s t-test). 
N = 4 to 6. 
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 Figure 18. The activity and mRNA expression of UGT2B1/3/6 at different time 
points after PHx. Sham: liver lobes from sham groups; PHx, the regenerated liver lobes 
after PHx. The activity was measured using liver microsomes prepared as described in 
the Methods section. The relative mRNA level was determined by real time PCR as 
described in Methods using pooled cDNAs generated from total RNAs from 6 normal 
livers as the standard. The arbitrary mRNA values were normalized with their respective 
beta-2-m values. All data are expressed as mean ± SD. ** P < .01 vs. sham; * P < .05 vs. 
sham (student’s t-test). N = 4 to 6. 
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 Figure 19. The activity and mRNA expression of UGT2B2 at different time points 
after PHx. Sham: liver lobes from sham groups; PHx, the regenerated liver lobes after 
PHx. The activity was measured using liver microsomes prepared as described in the 
Methods section. The relative mRNA level was determined by real time PCR as 
described in Methods using pooled cDNAs generated from total RNAs from 6 normal 
livers as the standard. The arbitrary mRNA values were normalized with their respective 
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beta-2-m values. All data are expressed as mean ± SD. ** P < .01 vs. sham (student’s 
t-test). N = 4 to 6. 
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 Figure 20. The activity and mRNA expression of UGT2B12 at different time points 
after PHx. Sham: liver lobes from sham groups; PHx, the regenerated liver lobes after 
PHx. The activity was measured using liver microsomes prepared as described in the 
Methods section. The relative mRNA level was determined by real time PCR as 
described in Methods using pooled cDNAs generated from total RNAs from 6 normal 
livers as the standard. The arbitrary mRNA values were normalized with their respective 
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beta-2-m values. All data are expressed as mean ± SD. ** P < .01 vs. sham; * P < .05 vs. 
sham (student’s t-test). N = 4 to 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 98
 Figure 21. The mRNA expression of UGT1A2, 1A3, 1A5, 1A8, and 2B8 at different 
time points after PHx. The relative mRNA level was determined by real time PCR as 
described in the Methods section using pooled cDNAs generated from total RNAs from 6 
normal livers as the standard. The arbitrary mRNA values were normalized with 
respective to beta-2-m values. Sham: liver lobes from sham groups; PHx, the regenerated 
liver lobes after PHx. All data are expressed as mean ± SD. ** P < .01 vs. sham; * P < 
.05 vs. sham (student’s t-test). N = 4 to 6. 
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 Figure 22. The mRNA expression of CAR, PXR, HNF1 and C/EBP α 24 hours after 
PHx. The relative mRNA level was determined by real time PCR as described in the 
Methods section using pooled cDNAs generated from total RNAs from 6 normal livers as 
the standard. The arbitrary mRNA values were normalized with their respective beta-2-m 
values. Sham: liver lobes from sham groups; PHx, the regenerated liver lobes after PHx. 
All data are expressed as mean ± SD. ** P < .01 vs. sham (student’s t-test). N= 5. 
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Discussion 
Limited and conflicting data have been published on the effect of hepatic regeneration on 
the expression and the activity of UGTs. The conjugation of bilirubin (UGT1A1 activity) 
in the liver has been reported to be preserved in rats after PHx (Catania et al., 1998), 
while the UGT1A1 mRNA expression has been shown to be decreased (Pellizzer et al., 
1996). In two studies, the conjugation of p-nitrophenol (UGT1A6 activity) was reported 
to be not altered after PHx in rats (Catania et al., 1998; Zakko et al., 1996). However, 
Iversen et al. reported decreased UGT1A6 (early stage) and induced UGT1A6 (later stage) 
activity for the glucuronidation of naphthol in rat livers at different time points after PHx 
(Iversen et al., 1985). The glucuronidation of morphine (UGT2B1 activity) has been 
reported to be decreased after PHx in rats (Iversen et al., 1985), while Pellizzer et al. 
reported the increased UGT2B1 mRNA expression in rat livers after PHx. The activity of 
rat UGT2B3 (testosterone) in rat livers has been reported to be altered after initiation of 
hepatic regeneration (Iversen et al., 1985) while Pellizzer et al. reported no change in the 
UGT2B3 mRNA expression in rat livers after PHx (Pellizzer et al., 1996). In these 
studies, the reported activity of different UGT isoforms during hepatic regeneration was 
inconsistent with the mRNA expression of these enzymes. No conclusive information 
about the regulation of UGTs can be obtained from published studies due to a lack of 
systematic studies. In this study, we used several currently available specific UGT 
markers to evaluate the activity of different UGT isoforms at different time points after 
initiation of hepatic regeneration. Real-time PCR provided more accurate, sensitive and 
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reliable measurements for the mRNA expression compared to northern blot. We used real 
time PCR to assess the effect of hepatic regeneration on the mRNA expression of these 
UGT isoforms. In addition, we measured the mRNA expression of additional UGTs using 
real-time PCR in this study because specific substrates or antibodies are not available for 
these isoforms. One major concern with mRNA measurements is the specificity of 
primers due to the high homology of different UGTs. We successfully designed the 
specific primers for all rat UGTs. The mRNA expression of all UGTs during hepatic 
regeneration was evaluated using specific primers. 
 
The estradiol-3-glucuronide formation rate has been verified and used as the marker for 
the human UGT1A1 activity (Senafi et al., 1994). There was no direct documentation of 
the specificity of estradiol as a substrate for the UGT1A1 activity in rats; however, rat 
and human UGT1A1 share more than 70% identity in their deduced primary amino acid 
sequences. Accordingly, rat and human UGT1A1 exhibited similar enzymatic efficiencies 
toward estrogens (including estradiol), flavonoids, phenols, and several other class of 
chemicals (King et al., 1996). It has been concluded that rat and human UGT1A1 are 
functionally similar and can be considered orthologous enzymes (King et al., 1996). 
Consequently it is highly possible that estradiol is also a rat UGT1A1 probe substrate. 
Based on these data, we used the formation rate of estradiol-3-glucuronidation as the 
marker of the UGT1A1 activity in rats in this study. 
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In contrast to the conflicting reports published from different studies, our results showed 
consistent changes in both the activity and the mRNA expression for all isoforms that we 
have studied. In addition, we also found that the mRNA expression of UGT1A2 and 
UGT1A3 mRNA was up-regulated during hepatic regeneration. The significance of this 
finding is unknown at this time due to the lack of rat UGT1A2 and UGT1A3 probe 
substrates and unknown clinically relevant drugs metabolized by this isoform. Similarly, 
because of the lack of known clinically relevant drugs metabolized by UGT2B8, the 
significance of the down-regulation of UGT2B8 is unknown at this time. 
 
Differential regulation of UGT isoforms has been reported in other systems. Our data of 
UGT1A6 and UGT2B1/3/6 were consistent with the observations in different systems. 
Acute-phase response induced by turpentine injection, leads to no reduction in the 
glucuronidation of p-nitrophenol (UGT1A6), while it impairs the glucuronidation of 
testosterone (UGT2B1/3/6) (Strasser et al., 1998). IL-6 can suppress the mRNA 
expression of UGT1A1 and UGT2B3 in rat hepatocytes (Strasser et al., 1998). Strasser et 
al. suggested that the promoter regions of some UGT isoforms may contain specific 
regulatory elements capable of responding to certain cytokines (Strasser et al., 1998). 
Several cytokines including TNF-α and IL-6 are involved in initiation of hepatic 
regeneration (Michalopoulos and DeFrances, 1997). Plasma concentration of IL-6 is 
significantly increased after initiation of hepatic regeneration (Matsunami et al., 1992; 
Fulop et al., 2001; Iwai et al., 2001). Cytokines such as TNF- α and IL-6 are reported to 
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inhibit the activity of UGT (Monshouwer et al., 1996; Strasser et al., 1998). So IL-6 is 
likely to be a contributor to the decreased activity and expression of UGTs after initiation 
of hepatic regeneration. 
 
Two nuclear receptors CAR and PXR have been implicated in the acute phase response 
mediated decrease in CYP activity (Beigneux et al., 2002). Since both CAR and PXR are 
also involved in the regulation of UGTs (Mackenzie et al., 2003), we expected altered 
levels of CAR and PXR in rat livers during hepatic regeneration. However, there was no 
change in CAR or PXR in the regenerating livers.  
 
There is also direct evidence showing that the C/EBP α knock-out is the cause for the loss 
of expression of UGT1A1 (bilirubin UGT) in mouse liver. In addition, HNF1 α binding 
site has been found in human UGT2B7 (Lee et al., 1997; Ishii et al., 2000). This would 
imply that C/EBP α and HNF1 α can also regulate the expression of UGTs (Mackenzie et 
al., 2003). We tested the expression level of C/EBP α and HNF1 in rat livers during hepatic 
regeneration. Only C/EBP α was down-regulated significantly after PHx. This suggests 
that C/EBP α is possibly an important factor responsible for the lower level of expression 
of UGTs during hepatic regeneration, even if not the only one. The differential activity and 
expression of different isoforms of UGT is probably due to the fact that UGTs are 
regulated by different factors. Additionally, it is likely that newly divided cells may have a 
much lower enzyme expression and activity compared to existing liver cells. 
 104
 This study systematically evaluated the activity and the mRNA expression of various 
UGTs during hepatic regeneration in rats and provided more consistent and accurate 
measurements of the regulation of different UGT isoforms. To the best of our knowledge, 
this is also the first study to measure various UGT isoforms in rats using real-time PCR 
with specific primers. Congiu et al. documented the specific primers for measuring 
human UGT isoforms using real-time PCR (Congiu et al., 2002); however, there were 
several mismatches between the primers and the target isoforms and the size of amplicons 
was out of the optimum range of 50-150 bp (efficient amplification within the range) for 
most UGT isoforms. Our study points to several important conclusions. 1) During hepatic 
regeneration, the mRNA expression of UGTs mirrors the activity of the corresponding 
isoform during hepatic regeneration; 2) The lower activity of UGT1A1 can decrease the 
conjugation of bilirubin and increase the concentration of biliribin in bile or serum during 
the early post operative period in the LDLT patients; 3) The doses of drugs that are 
metabolized by UGT will be decreased during early phase of LDLT; 4) Differential 
adjustment in doses of drugs metabolized by UGT is necessary in LDLT patients. 
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Chapter 5 In Vitro Hepatic Intrinsic Clearance and Pharmacokinetics of 
Mycophenolic Acid Are Transiently Altered during Hepatic Regeneration in Rats 
 
(Part of this chapter is the reprint with permission of the American Society for 
Pharmacology and Experimental Therapeutics. All rights reserved. Tian et al., 2005) 
 
Abstract 
Objective The objectives of this study were to evaluate 1) the hepatic metabolism of an 
immunosuppressive drug, mycophenolic acid (MPA), and 2) the pharmacokinetics of 
mycophenolic acid at various time points after initiation of hepatic regeneration in rats by 
partial hepatectomy (PHx). 
Methods The in vitro hepatic clearance of MPA was measured with liver microsomes 
incubated with different concentrations of MPA. The pharmacokinetics of mycophenolic 
acid was evaluated after intravenous administration of 20 mg/kg mycophenolic acid to 
partially hepatectomized rats. One hundred microlitter of blood was collected at 0, 1, 5, 
10, 15, 20, 30, 60, 90, 120, 240 and 480 minutes through a jugular vein catheter. The 
blood concentrations of MPA and MPA glucuronide (MPAG) were measured by a HPLC 
method. The plasma concentration vs. time profile was analyzed by a non-compartment 
model using WinNonlin. The glucuronidation of MPA in small intestine and kidney was 
assessed using kidney and intestine microsomes. The expression of multidrug 
Resistance-Associated Protein (Mrp) 2 and Mrp 3 was evaluated using western blot and 
quantitative PCR, respectively. 
Results The hepatic intrinsic clearance of MPA was decreased to 52% and 51% of that in 
Copyright 2004 by the American Society for Pharmacology and Experimental Therapeutics 
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control rats at the 24th hour and the 6th day, respectively but recovered to normal level by 
day 14. The total body clearance of MPA was reduced at twenty four hour after PHx but 
recovered by day 6. The elimination clearance of MPA glucuronide was also impaired 
during hepatic regeneration but recovered to normal with time. 
Conclusions During hepatic regeneration, the in vitro hepatic intrinsic clearance was 
significantly decreased and the clearance of MPA was also significantly but transiently 
decreased. By day 6 after initiation of hepatic regeneration, the intrinsic clearance of 
MPA recovered completely to normal. The ability of liver to clear MPA recovered much 
earlier than the complete recovery of liver mass. The magnitude of reduction in in vivo 
clearance of MPA was much less than what was predicted from the loss of liver mass and 
loss of enzyme activity in the residual liver. Overall glucuronide conjugation capacity of 
the regenerating liver recovered earlier than the CYP mediated metabolic capacity of the 
regenerating liver. 
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Introduction 
The liver plays an important role in the elimination of drugs and xenobiotics. During 
hepatic regeneration, the reduction in total liver mass due to partial hepatectomy (PHx) 
and the decreased activity of some UGTs are expected to reduce the ability of the liver to 
metabolize drugs. UGT is involved in the metabolism of the immunosuppressive drug, 
mycophenolic acid (MPA). The activity and expression of various forms of UGT were 
differentially regulated during hepatic regeneration (chapter 4). Therefore, it is important 
to understand whether the intrinsic activity of UGT is altered and whether the magnitude 
of change in the pharmacokinetics of immunosuppressive drugs metabolized by UGT 
during the hepatic regeneration process agrees with the predicted changes due to a 
decrease of liver mass and a decrease in the intrinsic activity of UGT during hepatic 
regeneration. Nothing is known about the pharmacokinetics of immunosuppressive drugs 
metabolized by UGT pathway during hepatic regeneration. Such knowledge will help in 
optimizing not only the immunosuppressive drug therapy but also therapy with other 
drugs that are metabolized by UGT pathway. We hypothesized that the in vitro intrinsic 
clearance of MPA will be reduced and that the in vivo systemic clearance of MPA will be 
reduced more than the loss of liver mass. We also hypothesized that the clearance of 
MPAG will be significantly decreased due to a reduction in liver mass during hepatic 
regeneration. In this study, we have utilized partially hepatectomized rats to study the 
effect of hepatic regeneration on the hepatic intrinsic clearance and the pharmacokinetics 
of MPA.
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 Materials and Methods 
Chemicals 
Mycophenolic acid was purchased from Sigma Chemical Co. (St. Louis, MO). 
Mycophenolic acid glucuronide was a generous gift from Roche Bioscience (Palo Alto, 
CA). Heparin injection (Lot No. 322024) was obtained from American Pharmaceutical 
Partners, Inc. (Los Angeles, CA). Mouse anti-human M2III-6 monoclonal antibody was 
obtained from ID Labs Inc. (London, ON, Canada). Horseradish peroxidase-conjugated 
donkey anti-rabbit IgG was purchased from Amersham Biosciences, (Piscataway, NJ). 
Western Chemiluminescence reagent was obtained from Perkin Elmer Life Sciences, Inc. 
(Boston, MA). All solvents used were of HPLC grade and were obtained from Fisher 
Scientific Inc. (Pittsburgh, PA). 
 
Animals 
The study protocol was approved by the IACUC at the University of Pittsburgh. Partial 
hepatectomy was performed according to the method of Higgins and Anderson in male 
Sprague-Dawley rats weighing 225-250 g (Higgins and Anderson, 1931) as described in 
Chapter 2. (For sham operation and definition of controls, please refer to Animals under 
Methods and Materials section in Chapter 2 also). Livers and kidneys were harvested 
as mentioned earlier (Animals under Methods and Materials section in Chapter 2) and 
small intestines were collected and processed immediately using the method described in 
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the next section (Preparation of microsomes).  
 
Preparation of Microsomes 
The livers and kidneys were prepared using the method mentioned in chapter 2 
(Microsome Preparation under Methods and Materials). Intestinal microsomes were 
prepared by the method described previously (Emoto et al., 2000): Immediately after 
excision of the small intestine, it was placed on a ice-cold stainless dish and cut 
longitudinally and washed with ice-cold salt solution containing 1 mM 
phenylmethylsulfonylfluoride (PMSF) and 1 mM EDTA. The mucosal cells were gently 
scraped off with a micro-cover glass. The scraped sample was mixed with 3X volumes 
ice-cold 50 mM Tris-HCl buffer containing 150 mM KCl, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 mg/ml trypsin inhibitor, 10 µM leupeptin, 0.04 unit/ml aprotinin, 1 
µM bestatin. After homogenization, the solution was centrifuged using the same 
procedure as that for preparation of liver microsomes. The pellets were reconstituted in 
50 mM Tris-HCl buffer containing 150 mM KCl, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 1 mg/ml trypsin inhibitor, 10 µM leupeptin, 0.04 unit/ml aprotinin and 1 µM 
bestatin. Microsomes were stored at -80°C before use. Microsomal protein concentrations 
were determined by Lowry’s method using bovine serum albumin as a standard (Lowry et 
al., 1951). Microsomes were stored at -80ºC until used in incubation studies. 
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Measurement of Vmax, Km, and CLint for the Formation of Mycophenolic Acid 
Glucuronide  in Hepatic Microsomes  
The incubation was carried out in a glass culture tube using varying concentrations of 
mycophenolic acid (MPA) (0-7.5 mM), 0.4 mg/ml microsomal protein (linear to 1 mg/ml, 
Figure 23), 10 mM MgCl2 and Brij58 (0.1 mg/mg microsomal protein) with the final 
volume adjusted to 0.2 ml by the addition of 0.05 M phosphate buffer (pH 7.4). The tubes 
were pre-incubated for 5 minutes at 37ºC and 4 mM UDPGA was added to initiate the 
reaction. After incubation for 30 minutes (linear to 60 min, Figure 24), the reaction was 
stopped by the addition of equal volume (0.2 ml) of ice-cold methanol. The tubes were 
centrifuged at 13,000 rpm at 4ºC for 5 minutes and the supernatants were frozen 
immediately at -80ºC. The formation of MPA glucuronide (MPAG) was measured using 
a HPLC method developed in our laboratory. (Column: LiChrospher column, C18, 5 µ, 
250 mm x 4.6 mm; column temperature: 38ºC; mobile phase: 25% acetonitrile:75% water 
containing 0.05% phosphoric acid, 1.00 ml/min; UV detector at 254 nm; injection 
volume: 30 µl; retention time: 11.8 min; total run time: 57 min) The standard curve was 
linear over the range of 1-100 µg/ml. The intra-day and inter-day CV(%) at 2.5 µg/ml, 25 
µg/ml and 100 µg/ml was less than 4% (n = 4). 
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 Figure 23. Relationship between microsomal protein concentration and the amount 
of MPAG formed in rat liver microsomes. MPA concentration: 2.5 mM; incubation 
time: 30 min. 
 
 
Figure 24. Relationship between time of incubation and the amount of MPAG 
formed in rat liver microsomes. MPA concentration: 2.5 mM; concentration of 
microsomal protein: 0.5 mg/ml. 
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Measurement of the Formation of Mycophenolic Acid Glucuronide in Small Intestine 
and Kidney Microsomes 
The incubation was conducted using the method described above with saturating MPA 
concentration of 5 mM (Km is less than 1 mM for both small intestine and kidney 
microsomes). The formation of MPAG was measured using the HPLC method as 
described above. 
 
Pharmacokinetics Study of MPA 
Pharmacokinetic studies were carried out in rats in the control group, 24 hours after PHx, 
6 days after PHx and 13 days after PHx. Since there was no significant difference 
between control group and the sham group in the in vitro intrinsic clearance of MPA at 
any time during hepatic regeneration, pharmacokinetic studies were not conducted in 
sham group. A silastic tubing was inserted into the jugular vein 24 hours before the study. 
Mycophenolic acid (20 mg/kg) was administered intravenously as a bolus through the 
jugular vein catheter. Multiple blood samples (150 µl) were collected in heparinized tubes 
at 0, 1, 5, 10, 15, 20, 30, 60, 90, 120, 240 and 480 minutes after intravenous 
administration of MPA. The concentration of MPA and MPAG in plasma was determined 
using a published method (Shipkova et al., 1998) with minor modifications as follows: to 
50 µl plasma, 50 µl of acetonitrile containing 100 µg/ml diazepam (internal standard) was 
added to precipitate the proteins. After centrifugation at 13,000 rpm for 5 min, 50 µl of 
supernatant was injected onto a LiChrospher RP-18 column (250 mm x 4.6mm, 5 µ) 
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heated to 38ºC. The mobile phase consisted of solution A (250 ml of acetonitrile and 750 
ml of 20 mmol/L phosphate buffer, pH 3.0) and solution B (700 ml of acetonitrile and 
300 ml of 20 mmol/L phosphate buffer, pH 6.5) that formed the following gradient:0-4.5 
min, 3% B; 4.5-5 min, 30% B; 5-12 min, 100% B; 12-17.5 min, 100% B; 17.5-18 min, 
3% B; 18-25 min, 3% B. The flow rate was 1.2 ml/min. The UV detector was set at 215 
nm. The retention time for MPAG, MPA, and diazepam was 5.7, 15.4 and 17.7 minutes, 
respectively, and the total run time was 25 minutes. The linearity of the method was from 
2 µg/ml to 100 µg/ml for both MPA and MPAG in plasma. The intra-day and inter-day 
CV(%) at 2 µg/ml, 25 µg/ml and 100 µg/ml was less than 7% (n = 4). 
 
Western Blot for Multidrug Resistance-Associated Protein (Mrp) 2 Protein Expression 
Liver membrane preparations were made as previously described (Ogawa et al., 2000): 
Liver was homogenized in 5 vols of 0.1 M Tris · HCl buffer (pH 7.4) containing 1 µg/ml 
leupeptin and pepstatin A and 50 µg/ml phenylmethylsulfonyl fluoride with a 
homogenizer. After an initial centrifugation at 1,500 g for 10 min, the supernatant was 
centrifuged at 100,000 g for 30 min. The pellet was suspended in Tris · HCl buffer and 
again centrifuged at 100,000 g for 30 min. The crude membrane fraction was resuspended 
in 0.1 M Tris · HCl buffer (pH 7.4) containing the proteinase inhibitors. Protein 
concentration was measured using Lowry’s method (Lowry et al., 1951). Western blot was 
performed using the published method (Slitter et al., 2003) with minor modifications: 45 
µg of membrane protein (without boiling, note: this is very critical) were 
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electrophoretically resolved using Bio-Rad 7.5% Ready gels and then transblotted 
overnight at 4°C onto PVDF (polyvinylidene difluoride) membrane (Millipore, Billerica, 
MA) with Tris-glycine buffer containing 20% methanol and 0.1% SDS. The blots were 
then blocked for 1 hour in 5% blocking grade nonfat dry milk (Bio-Rad, Hercules, CA) in 
TBS-Tween buffer (15 mM Trizma base, 154 mM sodium chloride, 0.05% Tween 20, pH 
7.4) at room temperature, incubated overnight at 4°C with mouse anti-human M2III-6 
monoclonal antibodies diluted in 0.5% nonfat dry milk (1:2000), and then washed three 
times for 15, 5 and 5 min, respectively, in TBS-Tween buffer. After the above washes, the 
blots were incubated for 1 h at room temperature with sheep anti-mouse IgG conjugated 
with horseradish peroxidase (Amersham Biosciences Inc., Piscataway, NJ), diluted 
1:10,000 in TBS-Tween buffer, and then subjected to three additional washes (15, 5, and 5 
min respectively). Mrp2 protein-antibody complexes were detected using ECL Western 
blotting reagents. 
 
Real-Time PCR for Mrp3 mRNA Expression   
The total RNA extraction, reverse transcription and real-time PCR were performed using 
the methods mentioned in chapter 2. Forward and reverse primers, designed using 
Primer Express 2.0 (Applied Biosystems), are 
5’-TCCCACTTCTCGGAGACAGTAAC-3’ (Forward), 
5’-CTTAGCATCACTGAGGACCTTGAA-3’ (Reverse) for Mrp3 and 
5’-CGTGCTTGCCATTCAGAAAA-3’ (Forward), 
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5’-GAAGTTGGGCTTCCCATTCTC-3’ for beta-2-microglobulin (beta-2-m). Cycling 
conditions were 1 cycle in 50ºC for 2 min, 1 cycle at 95ºC for 10 min, 50 cycles at 95ºC 
with 1 min annealing at 60ºC. The relative cDNA content was determined in duplicate 
using standard curves created from cDNA and normalized to beta-2-m for each sample. 
For each pair of primers, the control without reverse transcriptase was also used for PCR 
reactions in duplicate to confirm that there was no genomic DNA contamination in the 
cDNA samples. 
 
Data Analysis 
Enzyme kinetics analysis was carried out by nonlinear regression analysis using Prism 
3.0 (GraphPad Software Inc., San Diego, CA). The intrinsic formation clearance (CLint) 
was calculated by dividing the Vmax by the Km. Pharmacokinetics of MPA was analyzed by 
a non-compartmental model using WinNonlin 3.1 (Pharsight Co., Mountain View, CA). 
Area under curve (AUC) was calculated using the trapezoidal method. All data are 
reported as mean ± SD. Comparisons among multiple groups were made by one way 
analysis of variance with Tukey post hoc analysis (P < 0.05). Based on the initial 
measurement of AUC in control group, 2174.00 ± 229.02 min*µg/ml, to observe a 25% 
difference between groups, with a power of 80% and α = 0.05, the sample size required 
was 4 rats. Experiments were completed with 4 to 6 rats in each group. 
 
Results 
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Measurement of Vmax, Km, and CLint for the Formation of MPAG in Hepatic 
Microsomes 
Both Vmax and Km values were not different between control group and sham group at 
all time points studied. The Vmax for the formation of MPAG in hepatic microsomal 
fraction obtained at 24 hours after PHx was significantly decreased compared to control 
value (Table 6). On day 6, the Vmax still remained at the lower level (51% of control 
level), but recovered completely by day 14 with hepatic regeneration (96% of control 
level). However, the Km values were similar among all the groups. The intrinsic 
clearance (CLint) for the formation of MPAG in hepatic microsomal fraction was 
significantly decreased during hepatic regeneration at the 24th hour and on day 6.   
 
Pharmacokinetics of MPA  
The plasma concentration vs. time curves of MPA and MPAG after intravenous 
administration of MPA are shown in Figure 25. The pharmacokinetic parameters of MPA 
at different time points after initiation of hepatic regeneration are summarized in Table 7. 
The area under the plasma concentration vs time curve (AUC) for MPA, the total body 
clearance (CL) for MPA, the mean residence time (MRT) for MPA, the area under the 
plasma concentration vs time curve (AUC) for MPAG and the total body clearance (CL) 
for MPAG were significantly different between control and PHx rats. The total body 
clearance of MPA and MPAG at the 24th hour was significantly lower than that in the 
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control group. The clearance of MPA and MPAG recovered completely by day 6. The 
volume of distribution at steady state (Vss) was not altered. 
 
Measurement of Expression of Mrp2 and Mrp3 
The expression of Mrp2 was comparable among all the groups at the 24th hour after 
initiation of hepatic regeneration (Figure 26, panel A). The mRNA expression of Mrp3 
also remained similar among groups at the 24th hour after PHx (Figure 26, panel B).   
 
Measurement of the Formation of Mycophenolic Acid Glucuronide in Small Intestine 
and Kidney Microsomes  
The formation of MPAG by small intestine microsomes at the 24th hour after initiation of 
hepatic regeneration was not different from that in sham group (N = 5 rats); (PHx 24-hour 
vs. sham: 1.15 ± 0.50 vs. 1.04 ± 0.48 nmol/mg protein/min, P > .05, t-test). The formation 
of MPAG by the kidney microsomes from PHx 24-hour group was similar to that in sham 
group (N = 5 rats). (PHx 24-hour vs. sham: 0.29 ± 0.07 vs. 0.23 ± 0.06 nmol/mg 
protein/min, P > .05, t-test) 
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Table 6. Mean ( ± SD) Vmax, Km and CLint for the formation of mycophenolic acid 
glucuronide (MPAG) in hepatic microsomes (N = 4-6 rats). 
Time after PHx Groups Vm (nmol/mg 
protein/min) 
Km (mM) CLint (µl/min/mg 
protein)  
Control 1.75 ± 0.40 1.07 ± 0.22  1.62 ± 0.06 
Sham 1.88 ± 0.24  1.07 ± 0.18  1.79 ± 0.33 
 
24-hour 
PHx 0.89 ± 0.17a  1.06 ± 0.21 0.85 ± 0.20a
Control 1.84 ± 0.23  1.00 ± 0.19  1.87 ± 0.35 
Sham 1.90 ± 0.29  0.99 ± 0.18 1.98 ± 0.57 
 
6-day 
PHx 0.94 ± 0.10a 1.00 ± 0.23 0.96 ± 0.17a
Control 1.84 ± 0.23 0.90 ± 0.88 2.08 ± 0.36 
Sham 1.77 ± 0.30 0.94 ± 0.16 1.96 ± 0.60 
 
14-day 
PHx 1.76 ± 0.19 1.01 ± 0.24 1.80 ± 0.38 
a P < .01 (vs. control, Tukey post hoc analysis). 
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 Figure 25. Plasma concentration of MPA (panel A) and MPAG (panel B) vs time 
profile at different time points after initiation of hepatic regeneration. Data was 
represented by mean + SD (N = 4 to 5 rats). 
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TABLE 7. Pharmacokinetic parameters of MPA (20 mg/kg, i.v.) 24 hours, 6 days 
and 13 days after partial hepatectomy (N = 4 to 5 rats) 
Parameters Control PHx (24-hour) PHx (6-day) PHx (13-day) 
AUC 
(min•µg/ml) ** 
2174.00 ± 229.02 
 
3411.10 ± 250.01a 1821.50 ± 124.67 1987.03 ± 70.71 
CL 
(ml/min/kg)** 
9.29 ± 1.07 5.89 ± 0.42a 10.67 ± 0.43 10.07 ± 0.24 
MRT (min)** 37.84 ± 2.07 53.04 ± 8.41a 33.87 ± 9.40 36.37 ± 3.93 
Vss (ml/kg) 348.43 ± 44.18 293.01 ± 60.39 369.97 ± 88.76 429.03 ± 107.59 
(AUCMPAG)MPA 
(min*µg/ml)** 
4417.91 ± 850.02 7667.38 ± 
1088.84a
4283.66 ± 569.63 5153.61 ± 
455.53 
CLMPAG 
(ml/min/kg) ** 
4.66 ± 0.90 2.72 ± 0.41a 4.73 ± 0.57 3.90 ± 0.34 
** P < .01 for ANOVA; a P < .01, b P < .05 (vs. control) was obtained from Turkey post 
hoc analysis. 
** P < .01 for ANOVA; a P < .01, b P < .05 (vs. control) was obtained from Turkey post 
hoc analysis. CLMPAG was calculated using CLMPAG = fm*AUC*CL/(AUCMPAG)MPA 
(assuming fm = 1 because more than 95% MPA is metabolized to MPAG (sum of the 
amount excreted in urine and bile), Bullingham et al., 1996b). 
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Abbreviations: AUC, area under the plasma concentration of MPA vs time curve; CL, 
total body clearance of MPA; MRT = mean residence time of MPA ; Vss = volume of 
distribution at steady state; (AUCMPAG)MPA, area under the plasma concentration of MPAG 
vs time curve after intravenous administration of MPA; CLMPAG, total body clearance of 
MPAG after intravenous administration of MPA. 
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 Figure 26. Immunochemical analysis of Mrp2 protein expression (panel A) and 
mRNA expression of Mrp3 (panel B) from control livers, livers from the sham group, 
and livers from the 24-hour PHx group. Equal amounts of protein were loaded in each 
lane. Proteins from 6 rats were pooled together in each group. The relative mRNA level 
was determined by real time PCR as described in Methods using pooled cDNAs 
generated from total RNAs from 6 normal livers with different dilutions as the standard. 
The arbitrary mRNA values were normalized with their respective beta-2-m values. N = 
4-5. 
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Discussion  
In this study we have used partially hepatectomized rats to evaluate the effect of hepatic 
regeneration on the metabolism and pharmacokinetics of MPA. This study simulates 
what is likely to happen to the drug metabolizing capacity in the donor in a living donor 
liver transplant program. A recent study showed that human UGT 1A9 is the main 
isoform involved in the metabolism of MPA, with at least 55% contribution to the hepatic 
MPAG production. Additionally, UGT 1A1 and 1A6 probably account for a part of hepatic 
production of MPAG. UGT 1A7, 1A8, and 1A10, which are located in the small bowel, 
could contribute to intestinal first-pass effect of MPA (Picard et al., 2005). In this study, 
MPA was used as a representative marker drug for UGT enzyme(s).  
 
The magnitude of change in the total body clearance of MPA (37%) was much less than 
that in the liver mass (70%) at the 24th hour. So we evaluated the ability of the liver to 
metabolize MPA in vitro. The metabolism of MPA was also reduced in the regenerating 
liver at 24 hours and on day 6, but recovered to normal by day 14. Taking into 
consideration the decrease in the hepatic intrinsic clearance of MPA normalized to 
protein amount (assuming that hepatic MPA glucuronide formation clearance 
approximates the hepatic intrinsic clearance of MPA because 95% MPA is primarily 
metabolized to MPA glucuronide and only less than 1% of MPA was recovered in 
48-hour urine after both PO and IV dosing of MPA in humans, Bullingham et al., 1996a; 
Bullingham et al., 1996b) and the reduction in liver mass, the whole liver intrinsic 
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clearance for MPA must decrease to 16% of normal liver at the 24th hour after initiation 
of hepatic regeneration. Based on the total body clearance of MPA in control rats (9.29 
ml/min/kg) and the hepatic plasma flow 25.4 ml/min/kg in rats (estimated based on the 
reported hepatic blood flow of 55.2 ml/min/kg and hematocrit of approximately 46% in rats 
(Davies and Morris, 1993)), assuming lack of significant change in the unbound fraction 
of MPA as albumin, the total body clearance of MPA at the 24th hour should have been 
at most 2.12 ml/min/kg (If accounting for the three times increase of blood flow per unit 
liver weight (only 30% liver remaining), the total body clearance should have been at 
most 2.25 ml/min/kg) (using same equations and methods in the discussion part of 
chapter 3 to calculate this), and the total body clearance of MPA at the 6th day should 
have been at most 2.66 ml/min/kg. However, while the total body clearance of MPA was 
significantly decreased twenty four hours after PHx, the magnitude of reduction was 
much less than what was predicted based on in vitro data. Based on in vitro studies, even 
though our data showed that small instestines have the same metabolizing ability as livers 
(about four fold higer than that of kidneys) in rats when normalized to per unit organ 
mass, it was clear that extrahepatic pathways did not change and did not compensate for 
the reduction in hepatic metabolic capacity due to a much smaller organ mass. When 
normalized to the predicted liver weight at the 24th hours, the clearance per unit liver 
weight was increased significantly during hepatic regeneration (24-PHx vs. control: 0.49 
ml/min/g vs. 0.23 ml/min/g). This further supported the hypothesis of the presence of 
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significant reserve capacity of the liver to clear drugs due to increased percentage of 
hepatocytes to metabolize drugs compared to normal situation.  
 
Even though the pharmacokinetics of tacrolimus (chapter 3) and MPA were altered in a 
similar manner at the 24th hour during hepatic regeneration, the recovery profile for the 
pharmacokinetic parameters of tacrolimus and MPA was different at later stages of 
hepatic regeneration: 1) the total body clearance of MPA recovered much earlier than that 
of tacrolimus (6 days for MPA vs. 18 days for tacrolimus); and 2) total body clearance of 
MPA recovered earlier than in vitro metabolism of MPA (6 days for in vivo vs. 14 days 
for in vitro), but this is not the case for tacrolimus (18 days for in vivo vs. 14 days for in 
vitro). The reason for the differential recovery of the pharmacokinetic profile of 
tacrolimus and MPA may be due to the different reserve capacity of the regenerating 
livers for different metabolic pathways in which different metabolizing enzymes with 
different abundance are involved.  
 
In addition, we also observed a lower total body clearance of MPAG at the 24th hour 
during hepatic regeneration. In order to determine the reason(s) for this decrease, we 
evaluated the expression of Mrp2 and Mrp3, two transporters that are involved in the 
biliary excretion of MPAG (Kobayashi et al., 2004). However, no change was detected in 
the expression of Mrp2 or Mrp3 at the 24th hour, which ruled out any possible roles of 
Mrp2 and Mrp3 in the reduced clearance of MPAG. This observation is also consistant 
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with the published data showing the lack of change in the protein expression of Mrp 2 
(Chang et al., 2004; Vos et al., 1999). It is likely that the decrease in total body clearance 
of MPAG is partially due to the dramatic reduction in the number of hepatocytes leading 
to decreased bile formation in the regenerating liver. However, due to the small fraction 
of the MPAG being excreted in the bile (26% of the dose), the decreased bile formation is 
not the only mechanism or reason for the approximately two fold decrease in the total 
body clearance of MPAG during hepatic regeneration. There are other unknown 
mechanism(s) involved that are not apparent from this study such as the impaired 
function of both Mrp2 and Mrp3 (even though we observed the preserved expression of 
both transporters) because it takes time for newly generated cells to relocate to apical side 
of hepatocytes. 
 
To the best of our knowledge this is the first study to evaluate the pharmacokinetics of 
MPA and to analyze the recovery profile of the pharmacokinetics of MPA over time after 
initiation of hepatic regeneration in an animal model. Our study provides several 
implications for use of drugs metabolized by UGTs in LDLT patients. First, since the 
UGT activity is decreased after PHx, lower doses of UGT substrates may be necessary 
during the early postoperative period for LDLT patients. Second, the magnitude of the 
reduction in doses should be less than the magnitude of reduction in liver mass. Third, 
caution must be exercised in using in vitro data to predict in vivo clearance of drugs by 
the regenerating liver due to significant reserve capacity of the liver to clear drugs. 
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Finally, the recovery is different between oxidative pathway and conjugation pathway. 
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Chapter 6 Transiently Altered Acetaminophen Metabolism during Hepatic 
Regeneration in Rats 
 
Abstract 
Objective The objectives of this study were to evaluate 1) the dose-dependent in vivo 
metabolism of acetaminophen (APAP) 24 hours after hepatic regeneration, and 2) the 
time-dependent in vivo metabolism of APAP during hepatic regeneration. 
Methods The metabolism of APAP was evaluated by collecting urine (24 hrs) after 
intravenous administration of different doses of APAP to partially hepatectomized rats. 
The amount of APAP glucuronide, sulfate and mercapturate in the urine was measured by 
HPLC and LC/MS. 
Results The fraction of the dose that is converted to APAP sulfate was decreased 24 hours 
after regeneration at the doses of 100 mg/kg and 300 mg/kg. The fraction of the dose that 
is metabolized to APAP glucuronide and mercapturate was significantly increased 24 
hours after regeneration at the doses of 10 mg/kg and 100 mg/kg. At a dose of 10 mg/kg, 
the formation of APAP glucuronide and mercapturate significantly increased on day 6 and 
recovered on day 14, while the formation of APAP sulfate was not altered at any time 
during the hepatic regeneration. 
Conclusions The metabolism of APAP was altered during hepatic regeneration. There 
may be a higher risk for the APAP-induced toxicity during the early postoperative period 
in LDLT patients. Acetaminophen must be avoided during hepatic regeneration. The 
altered metabolism of APAP recovered to normal level by day 14 after initiation of 
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regeneration. It is safe to use APAP once the regeneration process is recovered 
completely. 
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Introduction: 
Acetaminophen (APAP) is the most widely used analgesic in the USA and overdoses of 
APAP are the leading causes of hospital admission for acute liver failure (Gill and 
Sterling, 2001). APAP is primarily metabolized by glucuronidation and sulfation in 
human, accounting for approximately 50% and 35% of a therapeutic dose, respectively 
(Forrest et al., 1982). Less than 10% of a therapeutic dose is metabolized to a reactive 
quinine form, N-acetyl-p-benzoquinone imine (NAPQI), mainly by CYP2E1 (Manyike et 
al., 2000), which can cause hepatotoxicity by forming adducts with critical proteins in the 
liver (Hinson et al., 1995; Holtzman, 1995). At low subtoxic doses, NAPQI is inactivated 
by GSTs through conjugation with reduced glutathione (GSH) (with subsequent 
conversions to cysteine and mercapturate conjugates of acetaminophen) (Moldeus, 1978; 
Van De Straat, 1986). Under an overdose situation, GSH is depleted so that NAPQI 
accumulates and binds to proteins (Davis et al., 1974; Jollow et al., 1974; Potter et al., 
1974).  
 
Humans have a limited capacity to conjugate APAP with sulfate. APAP sulfate formation 
may become capacity-limited (saturating) upon administration of a 2 g dose to adults 
(Levy and Yamada, 1971). A model that consists of two saturating biotransformation 
pathways (conjugation of APAP with glucuronic acid and with sulfate) as well as two 
apparent first-order processes (renal excretion of acetaminophen and oxidation of the 
drug to NAPQI) has been proposed to describe the pharmacokinetics of APAP (Slattery 
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and Levy, 1979). The limited capacity of the direct conjugation pathways causes a greater 
than proportional increase in the formation of NAPQI with increasing doses. 
 
In rats, after a single dose, the plasma APAP concentrations declined apparently 
exponentially, with a T1/2 that increased with increasing dose (Siegers et al., 1978; 
Galinsky and Levy, 1981). Studies have also confirmed that in rats, just as in man (Davis 
et al., 1976), the fraction of the dose that is converted to APAP sulfate decreases with 
increasing doses. So the APAP kinetics is dose-dependent. In several species, the 
metabolites of APAP are excreted through bile and urine. In principle, alterations in 
hepatobiliary or urinary excretion of APAP metabolites, as determined in in vivo animal 
studies, are indicative of changes in either APAP biotransformation or transport processes 
for these metabolites. 
 
During hepatic regeneration, the in vivo drug metabolizing activity of different enzymes 
or isoforms may be altered differentially as discussed in previous chapters, causing a shift 
in the relative contribution of different pathways to the overall disposition of a drug. 
Moreover, the reduction of liver mass will further decrease the drug metabolizing ability 
of the liver. Since the pharmacokinetics of acetaminophen is nonlinear and 
dose-dependent, we hypothesized that the formation of acetaminophen sulfate will 
decrease and the formation of glucuronide and NAPQI related metabolites (cysteine and 
mercapturate) will increase with an increase in dose or a reduction in the metabolizing 
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ability of the liver during hepatic regeneration. This change in the metabolic pathway, 
may predispose a LDLT patients to induced toxicity due to acetaminophen. 
 
Materials and Methods 
Chemicals 
Acetaminophen and acetaminophen glucuronide were purchased from Sigma Chemical 
Co. (St. Louis, MO). Acetaminophen sulfate, 3-cysteinyl acetaminophen, acetaminophen 
mercapturate, 2H3-labeled 3-cysteinyl acetaminophen and 2H3-labeled acetaminophen 
mercapturate were purchased from Toronto Research Chemicals (North York, ON, 
Canada).  
 
Experiment Procedure 
The study protocol was approved by the IACUC at the University of Pittsburgh. The 
sham operation and PHx were conducted as described in Chapter 2. Ten rats were 
ordered every time (5 rats for PHx; 5 rats for sham) and the surgery was conducted 
between 9:00 am and 11:00 am. APAP (APAP powder was dissolved in polyethylene 
glycol-0.9% saline (50:50, v/v) to make a final concentration of 5 mg/ml, 50 mg/ml and 
150 mg/ml) was injected through the jugular vein in sham operated (N = 5) and PHx (N = 
5) rats. Urine samples were collected for 24-hour using metabolic cages after IV 
administration of APAP. The urine samples were stored at -20ºC until analysis. 
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HPLC method 
After centrifugation at 13,000 rpm for 5 minutes, 40 µl of the supernatant (1 to 5 dilution 
for 100 mg/kg dosing or 1 to 15 dilution for 300 mg/kg dosing) was injected into HPLC. 
Acetaminophen glucuronide and sulfate were quantified by HPLC, as described 
previously (Wilson et al., 1982) (Column: LiChrospher column, C18, 5 µ, 250 mm x 4.6 
mm; mobile phase: methanol/glacial acetic acid/0.1 M KH2PO4 (7/0.75/92.25, v/v/v); UV, 
248 nm; retention time: 7.2 min for glucuronide and 13.3 min for sulfate). Quantitation 
was performed by comparison of the peak area for unknown samples to standard samples 
(linear from 0.8 µg to 6 µg for glucuronide; from 2.4 µg to 24 µg for sulfate) for APAP 
glucuronide and sulfate. The intra- and inter-day CV (%) for APAP glucuronide at 0.8 µg, 
2 µg and 6 µg were less than 9% (n =3). The intra- and inter-day CV (%) for APAP 
sulfate at 2.4 µg, 6 µg and 24 µg were less than 7% (n = 3).  
 
LC/MS method 
After centrifugation at 13,000 rpm for 5 minutes, 6 µl of supernatant (1 to 10 dilution for 
100 mg/kg dosing or 1 to 100 dilution for 300 mg/kg dosing), 6 µl of internal standard 
(2H3-labeled 3-cysteinyl acetaminophen, 40 µg/ml or 2H3-labeled acetaminophen 
mercapturate, 8 µg/ml) and 48 µl of water were mixed. 20 µl of the mixture was injected 
into LC/MS. The analysis of acetaminophen cysteine and mercapturate was performed on 
a Thermo Finnigan MSQ LC/MS, operated in the positive ion electrospray mode with 
selective ion monitoring. A YMC-AQ 2.1-µm, C18 (150 mm X 2 mm) column was used 
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for nominal chromatographic separation. The mobile phase consisted of methanol/1% 
acetic acid (20/80, v/v) delivered at a flow rate of 150 µl/min. The following mass 
spectrometric conditions were used: capillary and cone voltages of 3.0 kV and 50 V (for 
mercapturate) or 100 V (for cysteine), and a temperature of 300ºC. The following pairs 
of ions (unlabeled and deuterated internal standard) were detected by selective ion 
monitoring: mass-to-charge ratio (m/z) 271 and 274 (3-cysteinyl) and m/z 313 and 316 
(mercapturate). The retention time for 3-cysteinly APAP and APAP mercapturate was 4.7 
min and 11.7 min, respectively. 
 
The concentrations of all the metabolites were measured by comparison of the peak area 
ratios after the unknown samples to the standard curves for each metabolite. For 
measurement of 3-cysteinyl APAP and APAP mercapturate in urine, the respective inter- 
and intra-day CV (%) was less than 13% and 8% (n = 4), respectively. 
 
Data analysis 
The amount of APAP equivalent to the amount of each metabolite in the 24-hour urine 
was calculated by considering the difference in molecular weight between the metabolite 
and the parent drug. The fraction excreted in 24-hour urine for each metabolite was 
calculated as equivalent APAP amount divided by the IV dose of APAP. All data are 
reported as mean ± SD. Comparisons between two groups were made by student’s t-test 
(P < 0.5). For sample size calculation, the initial fraction of the formation of APAP 
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mercapturate from the sham group (24-hour time point) at the APAP dose of 10 mg/kg, 
1.01 ± 0.1%, was used. With a power of 80% and α = 0.05, to detect a 25% difference, 4 
rats were required. Experiments were completed with 5 rats in each group. 
 
Results 
Formation of Acetaminophen Glucuronide (Dose-dependent effect) 
The fraction of the dose that is excreted as APAP glucuronide in the 24 hr urine increased 
gradually with the increase in doses from 10 mg/kg to 300 mg/kg in the sham groups 
(Figure 27). During regeneration, there was a significant increase in the fraction of APAP 
glucuronide excreted in 24-hour urine at the doses of 10 mg/kg and 100 mg/kg compared 
to sham groups dosed with same amount of APAP. However, at a higher dose level, 300 
mg/kg, the formation of APAP glucuronide was the same for the PHx (24-hour) group as 
that for the sham group. 
 
Formation of Acetaminophen Sulfate (Dose-dependent effect) 
The fraction of the dose that is excrted as APAP sulfate in the 24 hr urine decreased with 
an increase in dose from 10 mg/kg to 300 mg/kg in the sham groups (Figure 28). Twenty 
four hours after the initition of regeneration, the fraction of APAP sulfate in 24-hour urine 
was not altered at the dose of 10 mg/kg. However, 24 hours after initiation of 
regeneration, the formation of APAP sulfate was significantly decreased at the doses of 
100 mg/kg and 300 mg/kg. 
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 Formation of Acetaminophen Mercapturate (Dose-dependent effect) 
The formation of APAP mercapturate also showed a dose-dependency (Figure 29). With 
an increase in the dose, the fraction of APAP converted to APAP mercapturate was 
increased in sham groups. At 24 hr after initiation of hepatic regeneration at the dose of 
10 mg/kg, the formation of APAP mercapturate was much higher in PHx (24-hour) group 
than in the sham group. The formation of APAP mercapturate was also much higher in 
PHx (24-hour) group than that in the sham group at the dose of 100 mg/kg. However, 24 
hr after initiation of hepatic regeneration, the formation of APAP mercapturate was not 
changed at the dose of 300 mg/kg. 
 
Formation of Acetaminophen Glucuronide (Time-dependent effect) 
At the dose of 10 mg/kg, greater amount of APAP was excreted as APAP glucuronide at 
the 24th hour and 6th after regeneration than that observed in sham groups (Figure 30). 
However, the percentage of dose excreted as APAP glucuronide returned to control level 
14 days after regeneration. 
 
Formation of Acetaminophen Sulfate (Time-dependent effect) 
At a dose of 10 mg/kg at the all time points after initiation of regeneration, the percentage 
of dose excreted as APAP sulfate was not changed when compared to sham groups 
(Figure 31). 
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 Formation of Acetaminophen Mercapturate (Time-dependent effect) 
The formation of APAP mercapturate was significantly increased 24 hours and 6 days 
after regeneration (Figure 32), but recovered to control level (as measured in the sham 
group) 14 days after initiation of regeneration. 
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 Figure 27. Formation of APAP glucuronide in 24-hour urine (dose-dependent effect). 
Sham: liver lobes from sham groups; PHx, the regenerated liver lobes after PHx. All data 
are expressed as mean ± SD. ** P < .01 vs. sham; * P < .05 vs. sham (student’s t-test). N 
= 5 rats. 
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 Figure 28. Formation of APAP sulfate in 24-hour urine (dose-dependent effect). 
Sham: liver lobes from sham groups; PHx, the regenerated liver lobes after PHx. All data 
are expressed as mean ± SD. * P < .05 vs. sham (student’s t-test). N = 5 rats. 
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 Figure 29. Formation of APAP mercapturate in 24-hour urine (dose-dependent 
effect). Sham: liver lobes from sham groups; PHx, the regenerated liver lobes after PHx. 
All data are expressed as mean ± SD. ** P < .01 vs. sham (student’s t-test). N = 5 rats. 
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 Figure 30. Formation of APAP glucuronide in 24-hour urine at the dose of 10 mg/kg 
(time-dependent effect). Sham: liver lobes from sham groups; PHx, the regenerated liver 
lobes after PHx. All data are expressed as mean ± SD. ** P < .01 vs. sham (student’s 
t-test). N = 5 rats. 
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 Figure 31. Formation of APAP sulfate in 24-hour urine at the dose of 10 mg/kg 
(time-dependent effect). Sham: liver lobes from sham groups; PHx, the regenerated liver 
lobes after PHx. All data are expressed as mean ± SD. P > .05 vs. sham (student’s t-test). 
N = 5 rats. 
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 Figure 32. Formation of APAP mercapturate in 24-hour urine at the dose of 10 mg/kg 
(time-dependent effect). Sham: liver lobes from sham groups; PHx, the regenerated liver 
lobes after PHx. All data are expressed as mean ± SD. ** P < .01 vs. sham (student’s 
t-test). N = 5 rats. 
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Discussion 
Acetaminophen is commonly recommended for analgesia or fever reduction. APAP 
toxicity, due to overdose, has been well documented. We used partially hepatectomized 
rats to study the in vivo metabolism of APAP during hepatic regeneration. We used a 
clinically relevant dose, 10 mg/kg, to study the time profile of APAP metabolism during 
hepatic regeneration. To study the dose-dependent effect 24 hours after initiation of 
regeneration, we used a clinically relevant dose of 10 mg/kg and two higher doses: 
subtoxic dose 100 and toxic dose 300 mg/kg.  
 
In this study, we observed dose-dependent formation of APAP glucuronide, APAP sulfate, 
and APAP mercapturate in the sham group, which is consistent with the reported 
non-linear pharmacokinetics of APAP in rats (Galinsky and Levy, 1981). A recent study 
showed significant time-dependent changes in APAP metabolism after liver 
transplantation (Park et al., 2003). At the early postoperative period (day 2 and day 10), 
the fraction of the dose that is excreted as 3-cysteinyl and mercapturate was significantly 
higher than day 180. The formation of APAP sulfate and glucuronide in the 24 hr urine 
was much lower on day 2 and 10. This may be due to impaired glucuronidation and 
sulfation and increase in the activity of CYP2E1 (Park et al., 2003; Burckat et al., 1998) 
 
We observed a higher fraction of APAP glucuronide and mercapturate being formed at 
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doses of 10 mg/kg and 100 mg/kg 24 hours after initiation of regeneration, however, the 
mechanism(s) responsible for our observations are different from those for the altered 
APAP metabolism after liver transplantation. This is due to 1) the increased amount of 
APAP that is perfused through the liver when normalized to unit liver mass and the result 
of non-linear pharmacokinetics of APAP (increased drug amount per unit liver mass will 
cause more APAP glucuronide and mercapturate to be formed). 2) the dramatic decease in 
the number of hepatocytes caused by the reduction of the liver mass will lead to 
decreased bililary excretion of APAP glucuronide (A study conducted in rats showed that 
the biliary excretion of APAP glucuronide (Mrp 2 substrate) (6.0-10 % of the dose) was 
equal to the urinary excretion of APAP glucuronide (6.0-10 % of the dose) at the dose of 
10 -100 mg/ml (Watari et al., 1983; Brouwer and Jones et al., 1990.). At the highest dose 
of 300 mg/kg, we didn’t see the change in the formation for both metabolites 
(glucuronide and mercapturate) 24 hours after regeneration, probably because of the 
saturation of both pathways to a similar magnitude. Even though APAP mercapturate is 
also excreted through the biliary excretion and is a Mrp 2 substrate, in rats, the percentage 
of the dose excreted in bile (less than 0.2% of the dose at the dose of 150 mg/kg to 300 
mg/kg) is much less than what is excreted in urine (1.2 – 2% of the dose at the dose of 
150 mg/kg to 300 mg/kg) (Kwak et al., 1998; Chen et al., 2003). So the decreased biliary 
excretion due to the decreased number of hepatocytes did not alter the urinary excretion 
of mercapturate. 3) the activity of drug metabolizing enzymes such as the CYP2E1, 
UGT1A6/7 and sulfotransfereases (SULTs) were altered differentially and will lead to the 
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shift in the relative contribution of different pathway to the overall elimilation of APAP. 
The CYP2E1 activity as measured by the formation of 6-hydroxychlorzoxazone was 
decreased to about the 57% of the control level as measured in sham group (PHx-24 hr vs. 
sham: 0.40 ± 0.12 vs. 0.69 ± 0.23 nmol/mg protein/min, P < .05, student’s t-test; N = 6 
rats, our observations), while the glucuronidation of acetaminophen was preserved after 
initiation of hepatic regeneration as shown in Chapter 5. Currently, there is no 
information on the activity of SULTs during hepatic regeneration; however, the mRNA 
expression of the isoforms of phenol SULT family (SULT1A1, 1B1, 1C1, and 1E2) which 
may be responsible for the formation of APAP sulfate has been showed to be decreased 
after initiation of hepatic regeneration (Dunn et al., 1999). Since the glucuronidation of 
APAP was preserved (chapter 4) and the activity of CYP2E1 (our observations) and 
expression SULTs were decreased (Dunn et al., 1999), there was increased amount of 
APAP glucuronide excreted in urine after initiation of hepatic regeneration. 
 
A lower fraction of the dose was excreted as APAP sulfate 24 hours after initiation of 
regeneration at doses of 100 mg/kg and 300 mg/kg compared to sham group. This is 
likely due to increased amount of drug being delivered per unit liver mass and the 
nonlinear pharmacokinetics of APAP (with the increase in dose, the fraction excreted as 
sulfate will decrease). This may be related to higher fraction (about 80%) of APAP 
excreted as APAP sulfate and inability to differentiate small changes.   
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This is the first study to document the altered metabolism of APAP during hepatic 
regeneration. Our data point to several important conclusions: 1) The metabolism of 
APAP will be altered during hepatic regeneration; 2) The formation of APAP glucuronide 
and mercapturate will be increased during hepatic regeneration at a clinically relevant 
dose; 3) There may be a higher risk for the APAP-induced toxicity in LDLT patients 
during the early post operative period; 4) The altered metabolism of APAP will recover to 
normal some time after regeneration and 5) Acetaminophen must be avoided during the 
hepatic regeneration in LDLT patients. 
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Chapter 7 Summary and Conclusions 
 
The goal of this dissertation is to evaluate the drug metabolizing capacity in 
regenerating liver in rats. 
 
Current observations 
 
The liver has a unique ability to regenerate. During hepatic regeneration, the clearance of 
several drugs are expected to be significantly altered due to 1) reduction in liver mass, 2) 
reduction in metabolic capacity of the phase I and phase II drug metabolizing enzymes, 3) 
increased hepatic blood flow (ml/kg) and 4) changes in plasma protein binding of a drug. 
Based on the inhibitory effects of some of the cytokines released during hepatic 
regeneration on the in vitro activity of both CYP and UGT isoforms and the changes in 
the expression of many known and unknown regulatory factors and other genes due to the 
acute phase response triggered by partial hepatectomy, we hypothesize that the in vitro 
activity of both CYP and UGT isoforms will be decreased during hepatic regeneration. 
Taking into consideration the reduction in liver mass, we further hypothesize that the in 
vivo clearance of drugs will be reduced more than the loss of liver mass during hepatic 
regeneration. The direction and magnititude of changes in clearance will be drug specific 
and will be influenced by changes in blood flow and changes in free fraction of drugs. 
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In intial experiments, we evaluated the effects of hepatic regeneration on the in vitro 
activity of CYP3A, the most significant CYP isoform, which contributes to the 
metabolism of more than 50% of the marketed drugs. We also measured the protein and 
mRNA expression level of CYP3A over a similar time period. Since during the hepatic 
regeneration process, the patients are expected to take immunosuppressive drugs such as 
cyclosporine A and tacrolimus which are known to be inhibitors of CYP3A but inducers 
of DNA synthesis, we also evaluated the effect of cyclosporine A and tacrolimus on 
CYP3A activity during hepatic regeneration. The changes in CYP3A during hepatic 
regeneration were consistent at the levels of activity, protein content and mRNA 
expression. The activity of CYP3A enzyme was impaired during the initial phase of 
hepatic regeneration but recovered completely at a later time. At the doses used, 
cyclosporine A and tacrolimus didn’t have any effect on CYP3A recovery in the 
regenerating liver. 
 
Secondly, in order to evaluate the feasibility of predicting in vivo changes in clearance 
during hepatic regeneration, we evaluated the pharmacokinetics of a CYP3A substrate, 
tacrolimus. The hepatic intrinsic clearance calculated as Vm/Km for the metabolism of 
tacrolimus and total body clearance of tacrolimus were significantly decreased 24 hours 
after PHx. Even though the hepatic intrinsic clearance for the metabolism of tacrolimus 
recovered completely 14 days after PHx, the total body clearance of tacrolimus returned 
to normal level only by day 18. Moreover, the observed clearance of tacrolimus was 
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greater than the predicted total body clearance based on our in vitro data. This indicates 
caution in using in vitro data to predict the in vivo clearance of CYP3A substrates because 
of the reserved hepatic capacity to metabolize drugs during hepatic regeneration. 
 
Thirdly, glucuronidation of several drugs has been reported to be differentially altered 
during hepatic regeneration. In this study, we evaluated either activity and/or mRNA 
expression level of various UGT isoforms after initiation of regeneration. The activity of 
different isoforms was altered differentially during hepatic regeneration with some having 
altered activity or expression while activity or expression of others was preserved. The 
mRNA expression of different UGT isoforms mirrored the activity of these isoforms. 
Moreover, different isoforms also recovered differentially during hepatic regeneration 
with some recovering 6 days after regeneration and others recovering 14 days after 
regeneration. The differential regulation of different UGT isoforms may be due to the 
differential expression of HNF-1 α and C/EBP α. 
 
Fourthly, we evaluated the clearance and in vitro metabolism of MPA, an 
immunosuppressive drug, during hepatic regeneration. The hepatic intrinsic clearance for 
the metabolism of MPA and the total body clearance of MPA were much lower 24 hours 
after regeneration. However, the recovery of the pharmacokinetic parameters including 
total body clearance was much earlier than the hepatic intrinsic clearance in vitro. The 
observed in vivo clearance of MPA during hepatic regeneration was greater than what was 
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predicted based on in vitro metabolism of MPA. The extrahepatic metabolism of MPA 
didn’t account for the increased clearance of MPA as the in vitro glucuronidation of MPA 
in small intestine and kidney was not altered during hepatic regeneration. Additionally, 
the total body clearance of MPA glucuronide (MPAG) was also significantly decreased 
during hepatic regeneration due to the dramatically decreased number of hepatocytes 
leading to decreased biliary excretion of MPAG. Two transporters, namely Mrp2 and 
Mrp3, which are involved in the biliary excretion of MPAG didn’t contribute to the 
decreased clearance of MPAG.  
 
When comparing the in vitro and in vivo data for the metabolism of both tacrolimus and 
mycophenolic acid, we also observed that 1) there was a difference between the in vivo 
recovery of oxidative pathway and conjugation pathway and 2) there was a disconnect  
between the in vitro recovery and the in vivo recovery. The clearance of CYP3A and UGT 
substrates studied eventually returned to normal in spite of incomplete recovery of liver 
mass. 
 
Finally, we evaluated the in vivo metabolism of APAP during hepatic regeneration. The 
dose-dependent effect of APAP metabolism with a higher fraction of APAP glucuronide 
and mercapturate was observed after regeneration at low, subtoxic and toxic doses of 
APAP. The time-dependent effect of APAP showed more APAP glucuronide and 
mercapturate formation at the early stage of regeneration. The altered metabolism of 
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APAP returned to normal even before the complete recovery of liver mass. 
 
Note: The summary of recovery of liver mass and in vitro activity of different drug 
metabolizing enzymes is shown on Figure 33. 
        
Figure 33. Summary of recovery of liver mass and in vitro activity of different drug 
metabolizing enzymes after hepatic regeneration. Percentage was calculated using 
mean value of PHx group divided by mean value of sham group. 
 
Clinical implications: 
1) Hepatic functional capacity will recover prior to the recovery of liver mass. 
2) Reduction in doses of drugs that are metabolized by CYP3A or UGT is necessary 
during the first few weeks after transplantation in living donor liver transplant donors 
and recipients. Additional factors such as cold ischemia, warm reperfusion injury and 
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immunological response may further alter the dosing regimen of drugs in the 
recipients. 
3) Reduction in clearance of the drug in vivo is not proportional to the reduction in liver 
mass. LDLT patients would require a dose of CYP3A or UGT substrates that is not in 
proportion to the loss of the liver mass. 
4) Differential adjustment in doses of drugs metabolized by different UGTs as compared 
to CYPs is necessary, as UGT pathway appear to recover faster than CYPs. 
5) The lower activity of UGT1A1 may lead to decreased conjugation of bilirubin and 
increase in the concentration of biliribin in bile or serum during the early part of 
hepatic regeneration process. 
6) Liver regeneration with regards to drug metabolizing ability proceeds normally in the 
presence of immunosuppressive therapy with cyclosporine A or tacrolimus. 
 
Future directions 
The studies presented in this dissertation have evaluated the drug metabolizing ability 
during hepatic regeneration. This studies conducted in the partially hepatectomized rats 
have significantly enhanced our understanding of both in vitro and in vivo drug 
metabolizing ability with regarding to phase I and phase II pathways. Some of this 
knowledge may be applied to LDLT patients, however, additional studies related to the 
mechanism and clinical relevance of our findings are needed in the future for better 
understanding the drug metabolizing ability during hepatic regeneration: 
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 A. The direct cause for the decreased activity and expression of some CYP and UGT 
isoforms needs to be identified and elucidated. Even though some cytokines are 
known to decrease the activity and expression of certain drug metabolizing enzymes, 
the direct role of cytokines as the gene regulation mediators during hepatic 
regeneration remains to be determined.  
 
B. Even though the differential regulation of UGTs during hepatic regeneration to be 
probably due to the differential expression of HNF-1 α and C/EBP α, the data 
presented in this dissertation is premature and the functional activity data of both 
regulatory factors in the UGT isoforms need to be extensively studied. Currently, 
there is only one functional activity study of the role of C/EBP α in the expression of 
UGT1A1 using C/EBP α knock-out mice. More UGT isoforms need to be evaluated 
using knock-out animals. 
 
C. The UGT isoforms we studied are rat isoforms. Even though humans and rats share 
most of UGT1A1 isoforms such as UGT1A1, 1A3, 1A5, 1A6, 1A7 and 1A8, not a 
single UGT2B isoform is shared between humans and rats. However, the substrates 
used for rat UGT2B isoforms in the studies are also known to be metabolized by 
glucuronidation in humans. So the change in specific human UGT isoforms may need 
to be evaluated using specific substrates in humans. 
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 D. We interpretated the discrepancy between the in vitro metabolism and in vivo 
clearance using the reserved hepatic capacity to metabolize drugs during hepatic 
regeneration. However, there is no any direct evidence to support this notion and the 
mechanism of hepatic capacity preservation is still unkown. 
 
E. The pharmacokinetic study using high clearance drug with extraction ratio near 1 is 
needed to see the effect of changes in blood flow during hepatic regeneration on drug 
clearance. 
 
F. We studied only IV dosing of drugs in this project. However, the change in clearance 
of drugs given orally due to the decreased first-pass effect caused by PHx needs to be 
evaluated during hepatic regeneration due to the decreased intrinsic clearance of 
drugs during hepatic regeneration. We anticipate that there will be more difference 
between PHx and control group in the clearance of drugs administrated orally than 
intravenously administration. 
 
G. The animal model used in this project reflects the donors and not the recipients. Other 
factors such as preexisting disease, cold ischemia, warm reperfusion injury and drug 
therapy such as antifungal drugs and antiviral drugs may also affect the drug 
metabolizing enzymes in vitro or in vivo in the recipients. The situations are expected 
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to be more complex in recipients and studies need to be conducted in different animal 
models reflecting the recipients. 
 
H. In addition to the enzyme that were evaluated in this project, other phase I and II 
enzymes also contribute to the clearance of drugs used in transplantation. Future 
studies should evaluate regulation and activity of such enzymes. 
 
I. In this study we primarily addressed hepatic drug metabolism. In addition to drug 
metabolism, drug transporters also play a significant role in the overall 
pharmacokinetics of drugs. Future studies should evaluate the regulation and activity 
of drug transporters during hepatic regeneration. 
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